EP0805854A1 - Immunogene zusammensetzungen welche rekombinant abgeschwächte pockenviren enthalten, die ein htlv antigen expremieren - Google Patents
Immunogene zusammensetzungen welche rekombinant abgeschwächte pockenviren enthalten, die ein htlv antigen expremierenInfo
- Publication number
- EP0805854A1 EP0805854A1 EP96902688A EP96902688A EP0805854A1 EP 0805854 A1 EP0805854 A1 EP 0805854A1 EP 96902688 A EP96902688 A EP 96902688A EP 96902688 A EP96902688 A EP 96902688A EP 0805854 A1 EP0805854 A1 EP 0805854A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- virus
- htlv
- alvac
- seq
- vaccinia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 239000000427 antigen Substances 0.000 title claims abstract description 41
- 108091007433 antigens Proteins 0.000 title claims abstract description 41
- 102000036639 antigens Human genes 0.000 title claims abstract description 41
- 230000002238 attenuated effect Effects 0.000 title claims abstract description 35
- 230000002163 immunogen Effects 0.000 title description 11
- 241000700605 Viruses Species 0.000 claims abstract description 242
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 claims abstract description 99
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 97
- 230000014509 gene expression Effects 0.000 claims abstract description 56
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 39
- 210000004027 cell Anatomy 0.000 claims description 166
- 241001465754 Metazoa Species 0.000 claims description 104
- 241000700618 Vaccinia virus Species 0.000 claims description 94
- 229960005486 vaccine Drugs 0.000 claims description 76
- 108700026244 Open Reading Frames Proteins 0.000 claims description 39
- 230000028993 immune response Effects 0.000 claims description 37
- 238000000338 in vitro Methods 0.000 claims description 28
- 230000001018 virulence Effects 0.000 claims description 27
- 241000178270 Canarypox virus Species 0.000 claims description 26
- 108020004440 Thymidine kinase Proteins 0.000 claims description 22
- 101710154606 Hemagglutinin Proteins 0.000 claims description 19
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 19
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 19
- 101710176177 Protein A56 Proteins 0.000 claims description 19
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 18
- 230000002068 genetic effect Effects 0.000 claims description 17
- 101150039990 B13R gene Proteins 0.000 claims description 16
- 101150071286 SPI-2 gene Proteins 0.000 claims description 16
- 230000006870 function Effects 0.000 claims description 15
- 230000001900 immune effect Effects 0.000 claims description 15
- 102000000505 Ribonucleotide Reductases Human genes 0.000 claims description 12
- 108010041388 Ribonucleotide Reductases Proteins 0.000 claims description 12
- 239000000185 hemagglutinin Substances 0.000 claims description 12
- 241000700663 Avipoxvirus Species 0.000 claims description 11
- 210000002950 fibroblast Anatomy 0.000 claims description 11
- 108091029865 Exogenous DNA Proteins 0.000 claims description 10
- 230000002008 hemorrhagic effect Effects 0.000 claims description 10
- 210000003837 chick embryo Anatomy 0.000 claims description 9
- 101100534084 Vaccinia virus (strain Copenhagen) B14R gene Proteins 0.000 claims description 8
- 101100004092 Vaccinia virus (strain Western Reserve) VACWR196 gene Proteins 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 8
- 108700026220 vif Genes Proteins 0.000 claims description 7
- 210000003000 inclusion body Anatomy 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 5
- 229920001817 Agar Polymers 0.000 claims description 4
- 239000008272 agar Substances 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- -1 and a large subunit Proteins 0.000 claims description 2
- 230000000717 retained effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 230000003449 preventive effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 108
- 239000013612 plasmid Substances 0.000 description 108
- 206010046865 Vaccinia virus infection Diseases 0.000 description 98
- 208000007089 vaccinia Diseases 0.000 description 98
- 238000011081 inoculation Methods 0.000 description 90
- 206010037742 Rabies Diseases 0.000 description 72
- 239000012634 fragment Substances 0.000 description 64
- 239000013598 vector Substances 0.000 description 63
- 238000012217 deletion Methods 0.000 description 60
- 230000037430 deletion Effects 0.000 description 60
- 108020004707 nucleic acids Proteins 0.000 description 58
- 102000039446 nucleic acids Human genes 0.000 description 58
- 150000007523 nucleic acids Chemical class 0.000 description 58
- 108020004414 DNA Proteins 0.000 description 56
- 239000002299 complementary DNA Substances 0.000 description 55
- 239000000047 product Substances 0.000 description 54
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 47
- 241000283973 Oryctolagus cuniculus Species 0.000 description 46
- 230000003902 lesion Effects 0.000 description 45
- 241000282414 Homo sapiens Species 0.000 description 37
- 238000012360 testing method Methods 0.000 description 37
- 241000271566 Aves Species 0.000 description 32
- 208000015181 infectious disease Diseases 0.000 description 32
- 230000006798 recombination Effects 0.000 description 30
- 230000003612 virological effect Effects 0.000 description 28
- 238000005215 recombination Methods 0.000 description 27
- 108091034117 Oligonucleotide Proteins 0.000 description 26
- 108010005774 beta-Galactosidase Proteins 0.000 description 25
- 238000003780 insertion Methods 0.000 description 24
- 230000037431 insertion Effects 0.000 description 24
- 238000002255 vaccination Methods 0.000 description 24
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 23
- 230000003053 immunization Effects 0.000 description 23
- 239000007924 injection Substances 0.000 description 23
- 238000002347 injection Methods 0.000 description 23
- 230000010076 replication Effects 0.000 description 23
- 238000002649 immunization Methods 0.000 description 22
- 230000001681 protective effect Effects 0.000 description 22
- 239000000523 sample Substances 0.000 description 22
- 108090000288 Glycoproteins Proteins 0.000 description 21
- 238000010276 construction Methods 0.000 description 20
- 230000003472 neutralizing effect Effects 0.000 description 20
- 238000003752 polymerase chain reaction Methods 0.000 description 20
- 102000003886 Glycoproteins Human genes 0.000 description 19
- 241000588724 Escherichia coli Species 0.000 description 18
- 241000282326 Felis catus Species 0.000 description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 description 18
- 230000000890 antigenic effect Effects 0.000 description 18
- 102000005936 beta-Galactosidase Human genes 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- 238000003556 assay Methods 0.000 description 17
- 210000005260 human cell Anatomy 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 16
- 241000282472 Canis lupus familiaris Species 0.000 description 15
- 241000282693 Cercopithecidae Species 0.000 description 15
- 101150039660 HA gene Proteins 0.000 description 15
- 230000029087 digestion Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 241000700662 Fowlpox virus Species 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 238000009825 accumulation Methods 0.000 description 13
- 230000034994 death Effects 0.000 description 13
- 231100000517 death Toxicity 0.000 description 13
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 12
- 101150060895 I4L gene Proteins 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 229960004397 cyclophosphamide Drugs 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 238000001114 immunoprecipitation Methods 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 230000036961 partial effect Effects 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 238000012809 post-inoculation Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 108010017826 DNA Polymerase I Proteins 0.000 description 11
- 102000004594 DNA Polymerase I Human genes 0.000 description 11
- 101001095863 Enterobacteria phage T4 RNA ligase 1 Proteins 0.000 description 11
- 241000711798 Rabies lyssavirus Species 0.000 description 11
- 238000007917 intracranial administration Methods 0.000 description 11
- 210000003501 vero cell Anatomy 0.000 description 11
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 10
- 108020005202 Viral DNA Proteins 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 238000002955 isolation Methods 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 230000004543 DNA replication Effects 0.000 description 9
- 241000725303 Human immunodeficiency virus Species 0.000 description 9
- 208000025865 Ulcer Diseases 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000002458 infectious effect Effects 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 238000004448 titration Methods 0.000 description 9
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 8
- 241000287828 Gallus gallus Species 0.000 description 8
- 206010060708 Induration Diseases 0.000 description 8
- 235000013330 chicken meat Nutrition 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000007918 intramuscular administration Methods 0.000 description 8
- 238000011580 nude mouse model Methods 0.000 description 8
- 244000052769 pathogen Species 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 238000011144 upstream manufacturing Methods 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 210000003371 toe Anatomy 0.000 description 7
- 230000036269 ulceration Effects 0.000 description 7
- 230000029812 viral genome replication Effects 0.000 description 7
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 6
- 241000282579 Pan Species 0.000 description 6
- 241000282695 Saimiri Species 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 238000002405 diagnostic procedure Methods 0.000 description 6
- 230000002779 inactivation Effects 0.000 description 6
- 238000009007 Diagnostic Kit Methods 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 101150082239 G gene Proteins 0.000 description 5
- 208000031886 HIV Infections Diseases 0.000 description 5
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 5
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 5
- 108091081024 Start codon Proteins 0.000 description 5
- 108010046722 Thrombospondin 1 Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 210000003292 kidney cell Anatomy 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 201000005737 orchitis Diseases 0.000 description 5
- 230000007918 pathogenicity Effects 0.000 description 5
- 230000000405 serological effect Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- 101710172503 Chemokine-binding protein Proteins 0.000 description 4
- 241000282552 Chlorocebus aethiops Species 0.000 description 4
- 241000700626 Cowpox virus Species 0.000 description 4
- 239000003155 DNA primer Substances 0.000 description 4
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 4
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 4
- 241000714165 Feline leukemia virus Species 0.000 description 4
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 231100000111 LD50 Toxicity 0.000 description 4
- 206010024769 Local reaction Diseases 0.000 description 4
- 241000282560 Macaca mulatta Species 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 238000010222 PCR analysis Methods 0.000 description 4
- 101710138270 PspA protein Proteins 0.000 description 4
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 241000287231 Serinus Species 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 108010008038 Synthetic Vaccines Proteins 0.000 description 4
- 102100036034 Thrombospondin-1 Human genes 0.000 description 4
- 206010044696 Tropical spastic paresis Diseases 0.000 description 4
- 241000700647 Variola virus Species 0.000 description 4
- 230000006978 adaptation Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 238000011587 new zealand white rabbit Methods 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000013615 primer Substances 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 229940124551 recombinant vaccine Drugs 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 208000006961 tropical spastic paraparesis Diseases 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 3
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 101710091045 Envelope protein Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108060002716 Exonuclease Proteins 0.000 description 3
- 208000000666 Fowlpox Diseases 0.000 description 3
- 241000282553 Macaca Species 0.000 description 3
- 235000014676 Phragmites communis Nutrition 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 208000000389 T-cell leukemia Diseases 0.000 description 3
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 108020005038 Terminator Codon Proteins 0.000 description 3
- 201000006966 adult T-cell leukemia Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 102000013165 exonuclease Human genes 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 229960003127 rabies vaccine Drugs 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 101150068401 BSL1 gene Proteins 0.000 description 2
- 101150011571 BSL2 gene Proteins 0.000 description 2
- 102100037084 C4b-binding protein alpha chain Human genes 0.000 description 2
- 101710159767 C4b-binding protein alpha chain Proteins 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101710177291 Gag polyprotein Proteins 0.000 description 2
- 208000005599 HTLV-I Infections Diseases 0.000 description 2
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 101100277251 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HEM12 gene Proteins 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 206010044688 Trisomy 21 Diseases 0.000 description 2
- 101100268528 Vaccinia virus (strain Copenhagen) A26L gene Proteins 0.000 description 2
- 101100268529 Vaccinia virus (strain Western Reserve) VACWR149 gene Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 108091092356 cellular DNA Proteins 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 201000003740 cowpox Diseases 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000001840 diploid cell Anatomy 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 108091008053 gene clusters Proteins 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- XVARCVCWNFACQC-RKQHYHRCSA-N indican Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=CC=C12 XVARCVCWNFACQC-RKQHYHRCSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 229940024231 poxvirus vaccine Drugs 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 229940049155 rabies serum Drugs 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 229940124954 vaccinia virus vaccine Drugs 0.000 description 2
- 230000017613 viral reproduction Effects 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 101100440894 Arabidopsis thaliana CP33 gene Proteins 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100021933 C-C motif chemokine 25 Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000006912 Complement C4b-Binding Protein Human genes 0.000 description 1
- 108010047548 Complement C4b-Binding Protein Proteins 0.000 description 1
- 101710184994 Complement control protein Proteins 0.000 description 1
- 102100037364 Craniofacial development protein 1 Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102100039282 Cytochrome P450 26A1 Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 229940122029 DNA synthesis inhibitor Drugs 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101000621107 Enterobacteria phage N4 Probable portal protein Proteins 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 206010069540 Generalised vaccinia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000897486 Homo sapiens C-C motif chemokine 25 Proteins 0.000 description 1
- 101000880187 Homo sapiens Craniofacial development protein 1 Proteins 0.000 description 1
- 101000745891 Homo sapiens Cytochrome P450 26A1 Proteins 0.000 description 1
- 101000875401 Homo sapiens Sterol 26-hydroxylase, mitochondrial Proteins 0.000 description 1
- 101900347674 Human T-cell leukemia virus 1 Matrix protein p19 Proteins 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010058461 Orchitis noninfective Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 206010069582 Progressive vaccinia Diseases 0.000 description 1
- 101000955367 Pseudomonas putida Transcriptional regulatory protein XylR Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000288960 Saguinus oedipus Species 0.000 description 1
- 241000282696 Saimiri sciureus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000287219 Serinus canaria Species 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 101100234922 Swinepox virus (strain Kasza) LAP gene Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 101800000385 Transmembrane protein Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 101100382200 Vaccinia virus (strain Ankara) MVA018L gene Proteins 0.000 description 1
- 101100382201 Vaccinia virus (strain Copenhagen) C7L gene Proteins 0.000 description 1
- 101100382202 Vaccinia virus (strain Western Reserve) VACWR021 gene Proteins 0.000 description 1
- 241000700622 Vaccinia virus Copenhagen Species 0.000 description 1
- 101900209501 Vaccinia virus Thymidine kinase Proteins 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- BXFFHSIDQOFMLE-UHFFFAOYSA-N indoxyl sulfate Natural products C1=CC=C2C(OS(=O)(=O)O)=CNC2=C1 BXFFHSIDQOFMLE-UHFFFAOYSA-N 0.000 description 1
- XVARCVCWNFACQC-UHFFFAOYSA-N indoxyl-beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CNC2=CC=CC=C12 XVARCVCWNFACQC-UHFFFAOYSA-N 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000037360 nucleotide metabolism Effects 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229940016590 sarkosyl Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 229940083538 smallpox vaccine Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000000966 temporal muscle Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000000427 trigeminal ganglion Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000007442 viral DNA synthesis Effects 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
- C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
- C12N2740/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the present invention relates to a modified poxvirus and to methods of making and using the same; for instance, a vaccinia virus or avipox (e.g. canarypox or fowlpox) , e.g., ( ⁇ • HTLV") modified recombinant poxvirus- hu an T-cell leukemia virus, such as an attenuated recombinant, especially a NYVAC or ALVAC HTLV recombinant. More in particular, the invention relates to improved vectors for the insertion and expression of foreign genes for use as safe immunization vehicles to elicit an immune response against HTLV virus.
- a vaccinia virus or avipox e.g. canarypox or fowlpox
- ⁇ • HTLV modified recombinant poxvirus- hu an T-cell leukemia virus, such as an attenuated recombinant, especially a NYVAC or ALVAC
- the invention relates to a recombinant poxvirus, which virus expresses gene products of HTLV and to immunogenic compositions which induce an immunological response against HTLV infections when administered to a host, or in vitro (e.g., ex vivo modalities) as well as to the products of expression of the poxvirus which by themselves are useful for eliciting an immune response e.g., raising antibodies, which antibodies are useful against HTLV infection, in either seropositive or seronegative individuals, or which expression products or antibodies elicited thereby, isolated from an animal or human or cell culture as the case may be, are useful for preparing a diagnostic kit, test or assay for the detection of the virus, or of infected cells, or, of the expression of the antigens or products in other systems.
- an immune response e.g., raising antibodies, which antibodies are useful against HTLV infection, in either seropositive or seronegative individuals, or which expression products or antibodies elicited thereby, isolated from an animal or human or
- the isolated expression products are especially useful in kits, tests or assays for detection of antibodies in a system, host, serum or sample, or for generation of antibodies.
- BACKGROUND OF THE INVENTION Vaccinia virus and more recently other poxviruses have been used for the insertion and expression of foreign genes.
- the basic technique of inserting foreign genes into live infectious poxvirus involves recombination between pox DNA sequences flanking a foreign genetic element in a donor plasirtid and homologous sequences present in the rescuing poxvirus (Piccini et al., 1987).
- the recombinant poxviruses are constructed in two steps known in the art and analogous to the methods for creating synthetic recombinants of poxviruses such as the vaccinia virus and avipox virus described in U.S. Patent Nos.
- the DNA gene sequence to be inserted into the virus is placed into an E. coli plasmid construct into which DNA homologous to a section of DNA of the poxvirus has been inserted.
- the DNA gene sequence to be inserted is ligated to a promoter.
- the promoter-gene linkage is positioned in the plasmid construct so that the promoter-gene linkage is flanked on both ends by DNA homologous to a DNA sequence flanking a region of pox DNA containing a nonessential locus.
- the resulting plasmid construct is then amplified by growth within E. coli bacteria (Clewell, 1972) and isolated (Clewell et al., 1969; Maniatis et al., 1982).
- the isolated plasmid containing the DNA gene sequence to be inserted is transfected into a cell culture, e.g. chick embryo fibroblasts, along with the poxvirus.
- a cell culture e.g. chick embryo fibroblasts
- Recombination between homologous pox DNA in the plasmid and the viral genome respectively gives a poxvirus modified by the presence, in a nonessential region of its genome, of foreign DNA sequences.
- the term ⁇ foreign" DNA designates exogenous DNA, particularly DNA from a non-pox source, that codes for gene products not ordinarily produced by the genome into which the exogenous DNA is placed.
- Genetic recombination is in general the exchange of homologous sections of DNA between two strands of DNA.
- RNA may replace DNA.
- Homologous sections of nucleic acid are sections of nucleic acid (DNA or RNA) which have the same sequence of nucleotide bases.
- Genetic recombination may take place naturally during the replication or manufacture of new viral genomes within the infected host cell. Thus, genetic recombination between viral genes may occur during the viral replication cycle that takes place in a host cell which is co-infected with two or more different viruses or other genetic constructs.
- a section of DNA from a first genome is used interchangeably in constructing the section of the genome of a second co-infecting virus in which the DNA is homologous with that of the first viral genome.
- recombination can also take place between sections of DNA in different genomes that are not perfectly homologous. If one such section is from a first genome homologous with a section of another genome except for the presence within the first section of, for example, a genetic marker or a gene coding for an antigenic determinant inserted into a portion of the homologous DNA, recombination can still take place and the products of that recombination are then detectable by the presence of that genetic marker or gene in the recombinant viral genome. Additional strategies have recently been reported for generating recombinant vaccinia virus.
- Successful expression of the inserted DNA genetic sequence by the modified infectious virus requires two conditions. First, the insertion must be into a nonessential region of the virus in order that the modified virus remain viable.
- the second condition for expression of inserted DNA is the presence of a promoter in the proper relationship to the inserted DNA. The promoter must be placed so that it is located upstream from the DNA sequence to be expressed.
- Vaccinia virus has been used successfully to immunize against smallpox, culminating in the worldwide eradication of smallpox in 1980.
- many strains of vaccinia have arisen. These different strains demonstrate varying immunogenicity and are implicated to varying degrees with potential complications, the most serious of which are post- vaccinial encephalitis and generalized vaccinia (Behbehani, 1983).
- the genetic background of the vaccinia vector has been shown to affect the protective efficacy of the expressed foreign immunogen.
- EBV Epstein Barr Virus
- expression of Epstein Barr Virus (EBV) gp340 in the Wyeth vaccine strain of vaccinia virus did not protect cottontop tamarins against EBV virus induced lymphoma, while expression of the same gene in the WR laboratory strain of vaccinia virus was protective (Morgan et al., 1988).
- a fine balance between the efficacy and the safety of a vaccinia virus-based recombinant vaccine candidate is extremely important.
- the recombinant virus roust present the immunogen(s) in a manner that elicits a protective immune response in the vaccinated animal but lacks any significant pathogenic properties. Therefore attenuation of the vector strain would be a highly desirable advance over the current state of technology.
- vaccinia genes have been identified which are non-essential for growth of the virus in tissue culture and whose deletion or inactivation reduces virulence in a variety of animal systems.
- TK vaccinia virus thymidine kinase
- herpes simplex virus type 2 intravaginal inoculation of guinea pigs with TK" virus resulted in significantly lower virus titers in the spinal cord than did inoculation with TK + virus (Stanberry et al., 1985). It has been demonstrated that herpesvirus encoded TK activity in vitro was not important for virus growth in actively metabolizing cells, but was required for virus growth in quiescent cells (Jamieson et al., 1974).
- TK vaccinia
- mice inoculated by the intracerebral and intraperitoneal routes Bacillus et al., 1985. Attenuation was observed both for the WR neurovirulent laboratory strain and for the Wyeth vaccine strain.
- TK " recombinant vaccinia generated equivalent anti-vaccinia neutralizing antibodies as compared with the parental TK + vaccinia virus, indicating that in this test system the loss of TK function does not significantly decrease immunogenicity of the vaccinia virus vector.
- mice with TK and TK + recombinant vaccinia virus Following intranasal inoculation of mice with TK" and TK + recombinant vaccinia virus (WR strain) , significantly less dissemination of virus to other locations, including the brain, has been found (Taylor et al., 1991a).
- ribonucleotide reductase Another enzyme involved with nucleotide metabolism is ribonucleotide reductase. Loss of virally encoded ribonucleotide reductase activity in herpes simplex virus (HSV) by deletion of the gene encoding the large subunit was shown to have no effect on viral growth and DNA synthesis in dividing cells in vitro , but severely compromised the ability of the virus to grow on serum starved cells (Goldstein et al., 1988).
- HSV herpes simplex virus
- the vaccinia virus hemagglutinin gene has been mapped and sequenced (Shida, 1986) .
- the HA gene of vaccinia virus is nonessential for growth in tissue culture (Ichihashi et al., 1971). Inactivation of the HA gene of vaccinia virus results in reduced neurovirulence in rabbits inoculated by the intracranial route and smaller lesions in rabbits at the site of intradermal inoculation (Shida et al., 1988).
- the HA locus was used for the insertion of foreign genes in the WR strain (Shida et al., 1987), derivatives of the Lister strain (Shida et al., 1988) and the Copenhagen strain (Guo et al., 1989) of vaccinia virus.
- Recombinant HA" vaccinia virus expressing foreign genes have been shown to be immunogenic (Guo et al., 1989; Itamura et al. , 1990; Shida et al., 1988; Shida et al., 1987) and protective against challenge by the relevant pathogen (Guo et al., 1989; Shida et al., 1987).
- Cowpox virus (Brighton red strain) produces red (hemorrhagic) pocks on the chorioallantoic membrane of chicken eggs. Spontaneous deletions within the cowpox genome generate mutants which produce white pocks (Pickup et al., 1984).
- the hemorrhagic function maps to a 38 kDa protein encoded by an early gene (Pickup et al., 1986) . This gene, which has homology to serine protease inhibitors, has been shown to inhibit the host inflammatory response to cowpox virus (Palumbo et al., 1989) and is an inhibitor of blood coagulation.
- the u gene is present in WR strain of vaccinia virus (Kotwal et al., 1989b). Mice inoculated with a WR vaccinia virus recombinant in which the u region has been inactivated by insertion of a foreign gene produce higher antibody levels to the foreign gene product compared to mice inoculated with a similar recombinant vaccinia virus in which the u. gene is intact (Zhou et al., 1990). The u region is present in a defective nonfunctional form in Copenhagen strain of vaccinia virus (open reading frames B13 and B14 by the terminology reported in Goebel et al., 1990a,b) .
- Cowpox virus is localized in infected cells in cytoplasmic A type inclusion bodies (ATI) (Kato et al., 1959) .
- the function of ATI is thought to be the protection of cowpox virus virions during dissemination from animal to animal (Bergoin et al., 1971).
- the ATI region of the cowpox genome encodes a 160 kDa protein which forms the matrix of the ATI bodies (Funahashi et al., 1988; Patel et al., 1987).
- Vaccinia virus though containing a homologous region in its genome, generally does not produce ATI.
- a WR strain of vaccinia virus with a 10 kb spontaneous deletion (Moss et al., 1981; Panicali et al., 1981) was shown to be attenuated by intracranial inoculation in mice (Buller et al., 1985). This deletion was later shown to include 17 potential ORFs (Kotwal et al., 1988b). Specific genes within the deleted region include the virokine NIL and a 35 kDa protein (C3L, by the terminology reported in Goebel et al., 1990a, ) . Insertional inactivation of NIL reduces virulence by intracranial inoculation for both normal and nude mice (Kotwal et al., 1989a).
- the 35 kDa protein is secreted like NIL into the medium of vaccinia virus infected cells.
- the protein contains homology to the family of complement control proteins, particularly the complement 4B binding protein (C4bp) (Kotwal et al., 1988a) .
- C4bp complement 4B binding protein
- the vaccinia 35 kDa protein binds the fourth component of complement and inhibits the classical complement cascade (Kotwal et al., 1990) .
- the vaccinia 35 kDa protein appears to be involved in aiding the virus in evading host defense mechanisms.
- the left end of the vaccinia genome includes two genes which have been identified as host range genes, KlL (Gillard et al., 1986) and C7L (Perkus et al., 1990). Deletion of both of these genes reduces the ability of vaccinia virus to grow on a variety of human cell lines (Perkus et al., 1990).
- avipox viruses Two additional vaccine vector systems involve the use of naturally host-restricted poxviruses, avipox viruses. Both fowlpoxvirus (FPV) and canarypoxvirus (CPV) have been engineered to express foreign gene products.
- Fowlpox virus (FPV) is the prototypic virus of the Avipox genus of the Poxvirus family. The virus causes an economically important disease of poultry which has been well controlled since the 1920 , s by the use of live attenuated vaccines.
- Replication of the avipox viruses is limited to avian species (Matthews, 1982) and there are no reports in the literature of avipoxvirus causing a productive infection in any non-avian species including man. This host restriction provides an inherent safety barrier to transmission of the virus to other species and makes use of avipoxvirus based vaccine vectors in veterinary and human applications an attractive proposition.
- FPV has been used advantageously as a vector expressing antigens from poultry pathogens.
- the hemagglutinin protein of a virulent avian influenza virus was expressed in an FPV recombinant (Taylor et al., 1988a) .
- an immune response was induced which was protective against either a homologous or a heterologous virulent influenza virus challenge (Taylor et al., 1988a).
- FPV recombinants expressing the surface glycoproteins of Newcastle Disease Virus have also been developed (Taylor et al., 1990; Edbauer et al., 1990).
- recombinants derived from these viruses were found to express extrinsic proteins in cells of nonavian origin. Further, such recombinant viruses were shown to elicit immunological responses directed towards the foreign gene product and where appropriate were shown to afford protection from challenge against the corresponding pathogen (Tartaglia et al., 1993a,b; Taylor et al., 1992; 1991b; 1988b).
- HTLV-I Human T-cell leukemia/lymphoma virus type I
- HSV human immunodeficiency virus
- retroviruses which causes adult T-cell leukemia (ATL) and tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM) , and acquired immunodeficiency syndrome (Gallo, 1987; Poiesz, 1980; Hinuma, 1981; Barre-Siniussi, 1983; Popovic, 1984; Gallo, 1986), respectively, are transmitted by close contact (e.g., sexual intercourse, mother-to-child) and transfusion of blood or blood products.
- close contact e.g., sexual intercourse, mother-to-child
- HTLV-I is genetically more complex than other animal oncornavirus and is the only human oncornavirus known in addition to HTLV-II (Kalyanaraman, 1982) .
- the genetic complexity of HTLV-I more closely resembles that of HIV (Gallo, 1986).
- HTLVs and HIVs share regulatory proteins with similar function (tax/tat, rex/rev) and a number of auxiliary genes [vpf, vif, nef, vpu for HIV-l (Haseltine, 1989), P12 1 , pl3 ⁇ , p30 ⁇ and p21 rex (Kiyokawa, 1985; Koralnik, 1993) for HTLV-I], which may be involved in adaptation of these pathogens for infecting human T-cells. Both viruses infect CD4 + T-cells in vivo and in vitro (6, 13, 14), but the HTLVs also infect other T-cell subtypes.
- HTLV-I products are beneficial, for instance, as an immunological composition or vaccine composition, or as a means to prepare such compositions, or for preparing HTLV-I products or antibodies thereto for assays, kits or tests, especially considering areas of the world where HTLV-I is endemic, such as parts of Japan, the Caribbean, parts of Africa and South America.
- HTLV-I env alone or in combination with a subunit boost of the purified HTLV-I precursor envelope protein (gp63) would be useful as an immunological or vaccine composition or to prepare antigens or antibodies for assays, kits or tests.
- Rabbits are very sensitive to HTLV-I infection but do not develop diseases resembling human ATL or TSP/HAM (Miyoshi, 1985) .
- HTLV-I infection of rabbits represents an economical and efficient animal model for vaccine studies.
- HTLV recombinant poxvirus and of compositions and products therefrom particularly NYVAC or ALVAC based HTLV recombinants and compositions and products therefrom, especially such recombinants containing coding for any or all of HTLV env , and compositions and products therefrom would be a highly desirable advance over the current state of technology.
- the present invention relates to a modified recombinant virus having inactivated virus- encoded genetic functions so that the recombinant virus has attenuated virulence and enhanced safety.
- the functions can be non-essential, or associated with virulence.
- the virus is advantageously a poxvirus, particularly a vaccinia virus or an avipox virus, such as fowlpox virus and canarypox virus.
- the modified recombinant virus can include, within a non-essential region of the virus genome, a heterologous DNA sequence which encodes an antigen or epitope derived from HTLV such as HTLV ⁇ nv .
- the present invention relates to an antigenic, immunological or vaccine composition or a therapeutic composition for inducing an antigenic or immunological response in a host animal inoculated with the composition, said vaccine including a carrier and a modified recombinant virus having inactivated nonessential virus-encoded genetic functions so that the recombinant virus has attenuated virulence and enhanced safety.
- the virus used in the composition according to the present invention is advantageously a poxvirus, particularly a vaccinia virus or an avipox virus, such as fowlpox virus and canarypox virus.
- the modified recombinant virus can include, within a non-essential region of the virus genome, a heterologous DNA sequence which encodes an antigenic protein, e.g., derived from HTLV, such as HTLV env .
- the present invention relates to an immunogenic composition containing a modified recombinant virus having inactivated nonessential virus- encoded genetic functions so that the recombinant virus has attenuated virulence and enhanced safety.
- the modified recombinant virus includes, within a non ⁇ essential region of the virus genome, a heterologous DNA sequence which encodes an antigenic protein (e.g., derived from HTLV, such as HTLV ⁇ nv ) wherein the composition, when administered to a host, is capable of inducing an immunological response specific to the antigen.
- an antigenic protein e.g., derived from HTLV, such as HTLV ⁇ nv
- the present invention relates to a method for expressing a gene product in a cell in vitro by introducing into the cell a modified recombinant virus having attenuated virulence and enhanced safety.
- the modified recombinant virus can include, within a nonessential region of the virus genome, a heterologous DNA sequence which encodes an antigenic protein, e.g. derived from HTLV such as HTLV env .
- the cells can then be reinfused directly into the individual or used to amplify specific reactivities for reinfusion (Ex vivo therapy) .
- the present invention relates to a method for expressing a gene product in a cell cultured in vitro by introducing into the cell a modified recombinant virus having attenuated virulence and enhanced safety.
- the modified recombinant virus can include, within a non-essential region of the virus genome, a heterologous DNA sequence which encodes an antigenic protein, e.g., derived from HTLV such as HTLV env .
- the product can then be administered to individuals or animals to stimulate an immune response.
- the antibodies raised can be useful in individuals for the prevention or treatment of HTLV and, the antibodies from individuals or animals or the isolated in vitro expression products can be used in diagnostic kits, assays or tests to determine the presence or absence in a sample such as sera of HTLV or antigens therefrom or antibodies thereto (and therefore the absence or presence of the virus or of the products, or of an immune response to the virus or antigens) .
- the present invention relates to a modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the virus has attenuated virulence, and wherein the modified recombinant virus further contains DNA from a heterologous source in a nonessential region of the virus genome.
- the DNA can code for HTLV such as HTLV env .
- the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor or by utilizing naturally host restricted viruses.
- the virus used according to the present invention is advantageously a poxvirus, particularly a vaccinia virus or an avipox virus, such as fowlpox virus and canarypox virus.
- the open reading frame is selected from the group consisting Of J2R, B13R + B14R, A26L, A56R, C7L - K1L, and I4L (by the terminology reported in Goebel et al., 1990a,b) ; and, the combination thereof.
- the open reading frame comprises a thymidine kinase gene, a hemorrhagic region, an A type inclusion body region, a hemagglutinin gene, a host range gene region or a large subunit, ribonucleotide reductase; or, the combination thereof.
- a suitable modified Copenhagen strain of vaccinia virus is identified as NYVAC (Tartaglia et al., 1992) , or a vaccinia virus from which has been deleted J2R, B13R+B14R, A26L, A56R, C7L-K11 and I4L or a thymidine kinase gene, a hemorrhagic region, an A type inclusion body region, a hemagglutinin gene, a host range region, and a large subunit, ribonucleotide reductase . See also U.S. Patent No. 5,364,773).
- a suitable poxvirus is an ALVAC or, a canarypox virus (Rentschler vaccine strain) which was attenuated, for instance, through more than 200 serial passages on chick embryo fibroblasts, a master seed therefrom was subjected to four successive plaque purifications under agar from which a plaque clone was amplified through five additional passages.
- the invention in yet a further aspect relates to the product of expression of the inventive recombinant poxvirus and uses therefor, such as to form antigenic, immunological or vaccine compositions for treatment, prevention, diagnosis or testing.
- FIG. 1 schematically shows a method for the construction of plasmid pSD460 for deletion of thymidine kinase gene and generation of recombinant vaccinia virus VP410
- FIG. 2 schematically shows a method for the construction of plasmid pSD486 for deletion of hemorrhagic region and generation of recombinant vaccinia virus vP553;
- FIG. 3 schematically shows a method for the construction of plasmid pMP494 ⁇ for deletion of ATI region and generation of recombinant vaccinia virus VP618;
- FIG. 4 schematically shows a method for the construction of plasmid pSD467 for deletion of hemagglutinin gene and generation of recombinant vaccinia virus vP723
- FIG. 5 schematically shows a method for the construction of plasmid pMPCKl ⁇ for deletion of gene cluster [C7L - K1L] and generation of recombinant vaccinia virus vP804
- FIG. 6 schematically shows a method for the construction of plasmid pSD548 for deletion of large subunit, ribonucleotide reductase and generation of recombinant vaccinia virus vP866 (NYVAC) ;
- FIG. 7 schematically shows a method for the construction of plasmid pRW842 for insertion of rabies glycoprotein G gene into the TK deletion locus and generation of recombinant vaccinia virus vP879;
- FIG. 8 shows the DNA sequence (SEQ ID NO:27) of a canarypox PvuII fragment containing the C5 ORF.
- FIGS. 9A and 9B schematically show a method for the construction of recombinant canarypox virus VCP65 (ALVAC- RG);
- FIG. 10 shows schematically the ORFs deleted to generate NYVAC
- FIGS. 11A to 11D show graphs of rabies neutralizing antibody titers (RFFIT, IU/ml) , booster effect of HDC and vCP65 (10 5,5 TCID 50 ) in volunteers previously immunized with either the same or the alternate vaccine (vaccines given at days 0, 28 and 180, antibody titers measured at days 0, 7, 28, 35, 56, 173, 187 and 208); and
- FIGS. 12 and 13 show serological analyses of animals inoculated With ALVAC, R-ALVAC (ALVAC-HTLV; VCP203), NYVAC, R-NYVAC (NYVAC-HTLV; VP1181) and challenged with HTLV-infected cells or blood. DETAILED DESCRIPTION OF THE INVENTION
- deletion loci were also engineered as recipient loci for the insertion of foreign genes.
- the regions deleted in NYVAC are listed below. Also listed are the abbreviations and open reading frame designations for the deleted regions (Goebel et al., 1990a,b) and the designation of the vaccinia recombinant (vP) containing all deletions through the deletion specified:
- TK thymidine kinase gene
- hemagglutinin gene (HA; A56R) vP723; (5) host range gene region (C7L - K1L) vP804; and (6) large subunit, ribonucleotide reductase (I4L) VP866 (NYVAC) .
- NYVAC is a genetically engineered vaccinia virus strain that was generated by the specific deletion of eighteen open reading frames encoding gene products associated with virulence and host range. NYVAC is highly attenuated by a number of criteria including i) decreased virulence after intracerebral inoculation in newborn mice, ii) inocuity in genetically (nu + /nu + ) or chemically (cyclophosphamide) immunocompromised mice, iii) failure to cause disseminated infection in immunocompromised mice, iv) lack of significant induration and ulceration on rabbit skin, v) rapid clearance from the site of inoculation, and vi) greatly reduced replication competency on a number of tissue culture cell lines including those of human origin.
- NYVAC based vectors induce excellent responses to extrinsic immunogens and provided protective immunity.
- TROVAC refers to an attenuated fowlpox that was a plaque-cloned isolate derived from the FP-l vaccine strain of fowlpoxvirus which is licensed for vaccination of 1 day old chicks.
- ALVAC is an attenuated canarypox virus-based vector that was a plaque-cloned derivative of the licensed canarypox vaccine, Kanapox (Tartaglia et al., 1992).
- ALVAC has some general properties which are the same as some general properties of Kanapox.
- ALVAC- based recombinant viruses expressing extrinsic immunogens have also been demonstrated efficacious as vaccine vectors (Tartaglia et al., 1993 a,b) .
- This avipox vector is restricted to avian species for productive replication.
- canarypox virus replication is aborted early in the viral replication cycle prior to viral DNA synthesis.
- PBMCs peripheral blood mononuclear cells derived from the ALVAC-RG vaccinates demonstrated significant levels of lymphocyte proliferation when stimulated with purified rabies virus (Fries et al., 1992) .
- NYVAC, ALVAC and TROVAC have also been recognized as unique among all poxviruses in that the National Institutes of Health (“NIH") (U.S. Public Health Service), Recombinant DNA Advisory Committee, which issues guidelines for the physical containment of genetic material such as viruses and vectors, i.e., guidelines for safety procedures for the use of such viruses and vectors which are based upon the pathogenicity of the particular virus or vector, granted a reduction in physical containment level: from BSL2 to BSL1.
- NASH National Institutes of Health
- HTLV-I human T-cell leukemia/lymphoma virus type I 1711
- the entire envelope protein of the human T-cell leukemia/lymphoma virus type I (HTLV-I) 1711 was expressed in the highly attenuated poxvirus vaccine vectors ALVAC and NYVAC.
- the poxvirus/HTLV-I env expression cassette was constructed by fusing the env sequences in a precise ATG for ATG configuration with the vaccinia virus early/immediate I3L promoter.
- Insertion plasmid pMAWOl ⁇ was generated by inserting the I3L/HTLV-I ⁇ nv expression cassette into the generic insertion plasmid pSPHA6. Plasmid pMAWOl ⁇ was used in in vitro recombination assays with NYVAC (VP866) as the rescuing virus to yield NYVAC HTLV-I env (vPll ⁇ l) .
- Insertion plasmid pMAW107 was generated by inserting the I3L/HTLV-I env expression cassette into the generic insertion plasmid pVQC5LSP6. Plasmid pMAW017 was used in standard in vitro recombination assays with ALVAC (vCPpp) as rescue virus to yield ALVAC HTLV-I env (VCP203) . This insertion placed the I3L/HTLV-I env expression cassette into the ALVAC C5 locus.
- Immunization regimens included inoculation of the poxvirus recombinant alone as well as prime-boost protocols using gp63 HTLV-I envelope precursor protein in Alum as the subunit boost.
- gp63 HTLV envelope precursor can also be administered with or after the inventive recombinants.
- All animals were exposed to a HTLV-I cell-associated challenge (5 x 10 4 cells) from a primary culture of the HTLV-I BOU isolate. The results indicated that two inoculations of 10 7 pfu of the ALVAC-based HTLV-I ⁇ nv vaccine candidate protected animals against viral challenge 5 months following the last immunization.
- compositions of the invention such as immunological, antigenic or vaccine compositions or therapeutic compositions can be via a parenteral route (intradermal, intramuscular or subcutaneous) . Such an administration enables a systemic immune response.
- compositions containing the poxvirus recombinants of the invention can be prepared in accordance with standard techniques well known to those skilled in the pharmaceutical art. Such compositions can be administered in dosages and by techniques well known to those skilled in the medical arts taking into consideration such factors as the age, sex, weight, and condition of the particular patient, and the route of administration.
- the compositions can be administered alone, or can be co-administered or sequentially administered with compositions of the invention or with other immunological, antigenic or vaccine or therapeutic compositions in seropositive individuals.
- compositions can be administered alone, or can be co- administered or sequentially administered with compositions of the invention or with other antigenic, immunological, vaccine or therapeutic compositions in seronegative individuals.
- Such other compositions can include purified antigens from HTLV or from the expression of such antigens by a recombinant poxvirus or other vector system or, such other compositions can include a recombinant poxvirus which expresses other HTLV antigens or biological response modifiers again taking into consideration such factors as the age, sex, weight, and condition of the particular patient, and, the route of administration.
- compositions of the invention include liquid preparations for orifice, e.g., oral, nasal, anal, vaginal, etc., administration such as suspensions, syrups or elixirs; and, preparations for parenteral, subcutaneous, intradermal, intramuscular or intravenous administration (e.g. , injectable administration) such as sterile suspensions or emulsions.
- parenteral, subcutaneous, intradermal, intramuscular or intravenous administration e.g. , injectable administration
- sterile suspensions or emulsions e.g., injectable administration
- the recombinant poxvirus may be in admixture with a suitable carrier, diluent, or excipient such as sterile water, physiological saline, glucose or the like.
- the products of expression of the inventive recombinant poxviruses can be used directly to stimulate an immune response in either seronegative or seropositive individuals or in animals.
- the expression products can be used in compositions of the invention instead or in addition to the inventive recombinant poxvirus in the aforementioned compositions.
- the inventive recombinant poxvirus and the expression products therefrom stimulate an immune or antibody response in humans and animals and therefore those products are antigens.
- monoclonal antibodies can be prepared and, those monoclonal antibodies or the antigens, can be employed in well known antibody binding assays, diagnostic kits or tests to determine the presence or absence of particular HTLV antigen(s) and therefore the presence or absence of the virus or expression of the antigen(s) (in HTLV or other systems) , or to determine whether an immune response to the virus or antigen(s) has simply been stimulated.
- inventive recombinants and compositions have numerous utilities, including:
- inventive recombinant poxvirus can be used directly to stimulate an immune response in either seronegative or seropositive individuals or in animals.
- inventive recombinant poxvirus can be used in compositions of the invention instead of or in addition to the inventive recombinant poxvirus.
- inventive recombinant poxvirus and the expression products therefrom stimulate an immune or antibody response in humans and animals.
- monoclonal antibodies can be prepared and, those monoclonal antibodies or the expression products of the inventive poxvirus and composition can be employed in well known antibody binding assays, diagnostic kits or tests to determine the presence or absence of particular HTLV antigen(s) or antibody(ies) and therefore the presence or absence of the virus, or to determine whether an immune response to the virus or antigen(s) has simply been stimulated.
- those monoclonal antibodies can also be employed in immunoadsorption chromatography to recover, isolate or detect HTLV or expression products of the inventive recombinant poxvirus.
- Methods for producing monoclonal antibodies and for uses of monoclonal antibodies, and, of uses and methods for HTLV antigens - the expression products of the inventive poxvirus and composition - are well known to those of ordinary skill in the art. They can be used in diagnostic methods, kits, tests or assays, as well as to recover materials by immunoadsorption chromatography or by immunoprecipitation.
- Monoclonal antibodies are immunoglobulins produced by hybridoma cells.
- a monoclonal antibody reacts with a single antigenic determinant and provides greater specificity than a conventional, serum-derived antibody. Furthermore, screening a large number of monoclonal antibodies makes it possible to select an individual antibody with desired specificity, avidity and isotype.
- Hybridoma cell lines provide a constant, inexpensive source of chemically identical antibodies and preparations of such antibodies can be easily standardized. Methods for producing monoclonal antibodies are well known to those of ordinary skill in the art, e.g., Koprowski, H. et al., U.S. Patent No.
- monoclonal antibodies Uses of monoclonal antibodies are known. One such use is in diagnostic methods, e.g., David, G. and Greene, H. U.S. Patent No. 4,376,110, issued March 8, 1983; incorporated herein by reference. Monoclonal antibodies have also been used to recover materials by immunoadsorption chromatography, e.g., Milstein, C. 1980, Scientific American 243:66, 70, incorporated herein by reference.
- inventive recombinant poxvirus or expression products therefrom can be used to stimulate a response in cells in vitro or ex vivo for subsequent reinfusion into a patient.
- the reinfusion is to stimulate an immune response, e.g. , an immunological or antigenic response such as active immunization.
- an immunological or antigenic response such as active immunization.
- the reinfusion is to stimulate or boost the immune system against HTLV.
- the inventive recombinant poxvirus has several utilities: In antigenic, immunological or vaccine compositions such as for administration to seronegative individuals. In therapeutic compositions in seropositive individuals in need of therapy to stimulate or boost the immune system against HTLV.
- antigens which can be further used in antigenic, immunological or vaccine compositions or in therapeutic compositions.
- antibodies either by direct administration or by administration of an expression product of the inventive recombinant poxvirus
- expression products or antigens which can be further used: in diagnosis, tests or kits to ascertain the presence or absence of antigens in a sample such as sera, for instance, to ascertain the presence or absence of HTLV in a sample such as sera or, to determine whether an immune response has elicited to the virus or, to particular antigen(s) ; or, in immunoadsorption chromatography, immunoprecipitation and the like.
- Synthetic oligodeoxyribonucleotides were prepared on a Biosearch 8750 or Applied Biosystems 380B DNA synthesizer as previously described (Perkus et al.,
- DNA sequencing was performed by the dideoxy-chain termination method (Sanger et al., 1977) using Sequenase (Tabor et al., 1987) as previously described (Guo et al., 1989) .
- DNA amplification by polymerase chain reaction (PCR) for sequence verification was performed using custom synthesized oligonucleotide primers and GeneAmp DNA amplification Reagent Kit (Perkin Elmer Cetus, Norwalk, CT) in an automated Perkin Elmer Cetus DNA Thermal Cycler.
- PCR polymerase chain reaction
- Excess DNA sequences were deleted from plasmids by restriction endonuclease digestion followed by limited digestion by BAL-31 exonuclease and mutagenesis (Mandecki, 1986) using synthetic oligonucleotides.
- the origins and conditions of cultivation of the Copenhagen strain of vaccinia virus and NYVAC has been previously described (Guo et al., 1989; Tartaglia et al., 1992) .
- Generation of recombinant virus by recombination, in situ hybridization of nitrocellulose filters and screening for B-galactosidase activity are as previously described (Panicali et al., 1982; Perkus et al., 1989).
- the parental canarypox virus (Rentschler strain) is a vaccinal strain for canaries.
- the vaccine strain was obtained from a wild type isolate and attenuated through more than 200 serial passages on chick embryo fibroblasts.
- a master viral seed was subjected to four successive plague purifications under agar and one plaque clone was amplified through five additional passages after which the stock virus was used as the parental virus in in vitro recombination tests.
- the plaque purified canarypox isolate is designated ALVAC.
- the strain of fowlpox virus (FPV) designated FP-1 has been described previously (Taylor et al., 1988a). It is an attenuated vaccine strain useful in vaccination of day old chickens.
- the parental virus strain Duvette was obtained in France as a fowlpox scab from a chicken. The virus was attenuated by approximately 50 serial passages in chicken embryonated eggs followed by 25 passages on chicken embryo fibroblast cells. The virus was subjected to four successive plaque purifications. One plaque isolate was further amplified in primary CEF cells and a stock virus, designated as TROVAC, established.
- NYVAC, ALVAC and TROVAC viral vectors and their derivatives were propagated as described previously (Piccini et al., 1987; Taylor et al., 1988a,b) .
- Vero cells and chick embryo fibroblasts (CEF) were propagated as described previously (Taylor et al., 1988a,b) .
- plasmid pSD406 contains vaccinia Hindlll J (pos. 83359 - 88377) cloned into pUC8.
- pSD406 was cut with Hindlll and PvuII. and the 1.7 kb fragment from the left side of Hindlll J cloned into pUC8 cut with Hindlll/Smal. forming pSD447.
- pSD447 contains the entire gene for J2R (pos. 83855 - 84385) .
- the initiation codon is contained within an Nlalll site and the termination codon is contained within an Sspl site.
- Direction of transcription is indicated by an arrow in FIG. 1.
- pSD447 was cut with SSPI (partial) within vaccinia sequences and Hindlll at the pUC/vaccinia junction, and a
- pSD460 was used as donor plasmid for recombination with wild type parental vaccinia virus Copenhagen strain VC-2.
- 32 P labelled probe was synthesized by primer extension using
- plasmid pSD419 contains vaccinia Sail G (pos. 160,744-173,351) cloned into pUC8.
- pSD422 contains the contiguous vaccinia Sail fragment to the right, Sail J (pos. 173,351-182,746) cloned into pUC8.
- U, B13R - B14R pos.
- pSD419 was used as the source for the left flanking arm and pSD422 was used as the source of the right flanking arm.
- the direction of transcription for the u region is indicated by an arrow in FIG. 2.
- sequences to the left of the Ncol site pos. 172,253 were removed by digestion of pSD419 with Ncol/Smal followed by blunt ending with Klenow fragment of E . coli polymerase and ligation generating plasmid pSD476.
- a vaccinia right flanking arm was obtained by digestion of pSD422 with Hpal at the termination codon of B14R and by digestion with Nrul 0.3 kb to the right.
- This 0.3 kb fragment was isolated and ligated with a 3.4 kb Hindi vector fragment isolated from pSD476, generating plasmid pSD477.
- the location of the partial deletion of the vaccinia u region in pSD477 is indicated by a triangle.
- the remaining B13R coding sequences in pSD477 were removed by digestion with Clal/Hpal, and the resulting vector fragment was ligated with annealed synthetic oligonucleotides SD22mer/SD20mer
- pSD479 contains an initiation codon (underlined) followed by a BamHI site.
- E . coli Beta-galactosidase in the B13-B14 (u) deletion locus under the control of the u promoter, a 3.2 kb BamHI fragment containing the Beta-galactosidase gene (Shapira et al., 1983) was inserted into the BamHI site of pSD479, generating pSD479BG.
- pSD479BG was used as donor plasmid for recombination with vaccinia virus vP410.
- Recombinant vaccinia virus vP533 was isolated as a blue plaque in the presence of chromogenic substrate X-gal.
- vP533 the B13R-B14R region is deleted and is replaced by Beta- galactosidase.
- plasmid pSD486 a derivative of pSD477 containing a polylinker region but no initiation codon at the u deletion junction, was utilized.
- Clal/Hpal vector fragment from pSD477 referred to above was ligated with annealed synthetic oligonucleotides SD42mer/SD40mer (SEQ ID NO:8/SEQ ID NO:9)
- HEM5/HEM6 (SEQ ID N0:10/SEQ ID NO:11) BamHI EcoRI HPal
- pSD486 was used as donor plasmid for recombination with recombinant vaccinia virus vP533, generating vP553, which was isolated as a clear plaque in the presence of X-gal.
- pSD414 contains Sail B cloned into pUC8.
- pSD414 was cut with Xbal within vaccinia sequences (pos. 137,079) and with Hindlll at the pUC/vaccinia junction, then blunt ended with Klenow fragment of E. coli polymerase and ligated, resulting in plasmid pSD483.
- pSD483 was cut with EcoRI (pos. 140,665 and at the pUC/vaccinia junction) and ligated, forming plasmid pSD484.
- pSD484 was cut with Ndel (partial) slightly upstream from the A26L ORF (pos. 139,004) and with Hpal (pos. 137,889) slightly downstream from the A26L ORF.
- the 5.2 kb vector fragment was isolated and ligated with annealed synthetic oligonucleotides ATI3/ATI4 (SEQ ID NO:12/SEQ ID NO:13)
- ATI4 reconstructing the region upstream from A26L and replacing the A26L ORF with a short polylinker region containing the restriction sites Bglll. EcoRI and Hpal. as indicated above.
- the resulting plasmid was designated pSD485. Since the Bglll and EcoRI sites in the polylinker region of pSD485 are not unique, unwanted Bgl . II and EcoRI sites were removed from plasmid pSD483 (described above) by digestion with Bglll (pos. 140,136) and with EcoRI at the pUC/vaccinia junction, followed by blunt ending with Klenow fragment of E.
- the resulting plasmid was designated pSD489.
- the 1.8 kb Clal (pos. 137,198)/JgeoRV (pos. 139,048) fragment from pSD489 containing the A26L ORF was replaced with the corresponding 0.7 kb polylinker- containing Clal/EcoRV fragment from pSD485, generating pSD492.
- the Bglll and EcoRI sites in the polylinker region of pSD492 are unique.
- a 3.3 kb ggJ.II cassette containing the E . coli Beta- galactosidase gene (Shapira et al., 1983) under the control of the vaccinia 11 kDa promoter (Bertholet et al., 1985; Perkus et al., 1990) was inserted into the Bglll site of pSD492, forming pSD493KBG. Plasmid pSD493KBG was used in recombination with rescuing virus vP553. Recombinant vaccinia virus, vP581, containing Beta-galactosidase in the A26L deletion region, was isolated as a blue plaque in the presence of X-gal.
- plasmid pSD492 was deleted by mutagenesis (Mandecki, 1986) using synthetic oligonucleotide MPSYN177 (SEQ ID NO:14) (5' AAAATGGGCGTGGATTGTTAACTTTATATAACTTATTTTTTGAATATAC 3 ' ) .
- MPSYN177 synthetic oligonucleotide MPSYN177 (SEQ ID NO:14) (5' AAAATGGGCGTGGATTGTTAACTTTATATAACTTATTTTTTGAATATAC 3 ' ) .
- MPSYN177 synthetic oligonucleotide MPSYN177
- vaccinia DNA encompassing positions [137,889 - 138,937], including the entire A26L ORF is deleted.
- vaccinia Sail G restriction fragment (pos. 160,744-173,351) crosses the Hindlll A/B junction (pos. 162,539).
- pSD419 contains vaccinia Sail G cloned into pUC8.
- the direction of transcription for the hemagglutinin (HA) gene is indicated by an arrow in FIG. 4.
- Vaccinia sequences derived from Hindlll B were removed by digestion of pSD419 with Hindlll within vaccinia sequences and at the pUC/vaccinia junction followed by ligation.
- the resulting plasmid, pSD456 contains the HA gene, A56R, flanked by 0.4 kb of vaccinia sequences to the left and 0.4 kb of vaccinia sequences to the right.
- A56R coding sequences were removed by cutting pSD456 with Rsal (partial; pos. 161,090) upstream from
- the resulting plasmid is pSD466.
- the vaccinia deletion in pSD466 encompasses positions [161,185-162,053].
- the site of the deletion in pSD466 is indicated by a triangle in FIG. 4.
- coli Beta-galactosidase gene (Shapira et al., 1983) under the control of the vaccinia 11 kDa promoter (Bertholet et al., 1985; Guo et al., 1989) was inserted into the Bglll site of pSD466, forming pSD466KBG. Plasmid pSD466KBG was used in recombination with rescuing virus vP618. Recombinant vaccinia virus, vP708, containing Beta-galactosidase in the A56R deletion, was isolated as a blue plaque in the presence of X-gal.
- Beta-galactosidase sequences were deleted from vP708 using donor plasmid pSD467.
- pSD467 is identical to pSD466, except that EcoRI. Smal and BamHI sites were removed from the pUC/vaccinia junction by digestion of pSD466 with EcoRI/BamHI followed by blunt ending with
- pSD420 is Sail H cloned into pUC8.
- pSD435 is Kpnl F cloned into pUC18.
- pSD435 was cut with SphI and religated, forming pSD451.
- DNA sequences to the left of the SphI site (pos. 27,416) in Hindlll M are removed (Perkus et al., 1990).
- pSD409 is Hindlll M cloned into pUC8.
- E. coli Beta- galactosidase was first inserted into the vaccinia M2L deletion locus (Guo et al., 1990) as follows. To eliminate the Bglll site in pSD409, the plasmid was cut with Bglll in vaccinia sequences (pos. 28,212) and with BamHI at the pUC/vaccinia junction, then ligated to form plasmid pMP409B. pMP409B was cut at the unique SphI site
- M2L coding sequences were removed by mutagenesis (Guo et al., 1990; Mandecki, 1986) using synthetic oligonucleotide
- the resulting plasmid, pMP409D contains a unique Bglll site inserted into the M2L deletion locus as indicated above.
- the resulting plasmid, pMP409DBG (Guo et al., 1990), was used as donor plasmid for recombination with rescuing vaccinia virus vP723.
- the left flanking arm consisting of vaccinia Hindlll C sequences was obtained by digestion of pSD420 with Xbal (pos. 18,628) followed by blunt ending with Klenow fragment of E. coli polymerase and digestion with Bglll (pos. 19,706).
- the right flanking arm consisting of vaccinia Hindlll K sequences was obtained by digestion of pSD451 with Bglll (pos. 29,062) and EcoRV (pos. 29,778).
- the resulting plasmid, pMP581CK is deleted for vaccinia sequences between the Bglll site (pos. 19,706) in Hindlll C and the Bglll site (pos. 29,062) in Hindlll K.
- the site of the deletion of vaccinia sequences in plasmid pMP581CK is indicated by a triangle in FIG. 5.
- plasmid pMP581CK was cut at the Ncol sites within vaccinia sequences (pos. 18,811; 19,655), treated with Bal-31 exonuclease and subjected to mutagenesis (Mandecki, 1986) using synthetic oligonucleotide MPSYN233 (SEQ ID NO:20)
- pMPCSKl ⁇ 5'-TGTCATTTAACACTATACTCATATTAATAAAAATAATATTTATT-3' .
- the resulting plasmid, pMPCSKl ⁇ is deleted for vaccinia sequences positions 18,805-29,108, encompassing 12 vaccinia open reading frames [C7L - K1L] .
- plasmid pSD405 contains vaccinia Hindlll I (pos. 63,875-70,367) cloned in pUC8.
- pSD405 was digested with EcoRV within vaccinia sequences (pos. 67,933) and with Smal at the pUC/vaccinia junction, and ligated, forming plasmid pSD518.
- pSD518 was used as the source of all the vaccinia restriction fragments used in the construction of pSD548.
- the vaccinia I4L gene extends from position 67,371- 65,059. Direction of transcription for I4L is indicated by an arrow in FIG. 6.
- pSD518 was digested with BamHI (pos. 65,381) and Hpal (pos. 67,001) and blunt ended using Klenow fragment of E. coli polymerase. This 4.8 kb vector fragment was ligated with a 3.2 kb Smal cassette containing the E.
- coli Beta-galactosidase gene (Shapira et al., 1983) under the control of the vaccinia 11 kDa promoter (Bertholet et al., 1985; Perkus et al., 1990), resulting in plasmid pSD524KBG.
- pSD524KBG was used as donor plasmid for recombination with vaccinia virus vP804.
- Recombinant vaccinia virus, vP855, containing Beta-galactosidase in a partial deletion of the I4L gene was isolated as a blue plaque in the presence of X-gal.
- deletion plasmid pSD548 was constructed.
- the left and right vaccinia flanking arms were assembled separately in pUC8 as detailed below and presented schematically in FIG. 6.
- pUC8 was cut with BamHI/EcoRI and ligated with annealed synthetic oligonucleotides 518A1/518A2 (SEQ ID N0:21/SEQ ID NO:22) BamHI Rsal 518A1 5'
- pUC8 was cut with BamHI/EcoRI and ligated with annealed synthetic oligonucleotides
- the right vaccinia flanking arm was isolated as a 0.6 kb EcoRI/Bglll fragment from pSD538 and ligated into pSD537 vector plasmid cut with EcoRI/Bglll.
- the I4L ORF pos. 65,047- 67,386
- a polylinker region which is flanked by 0.6 kb vaccinia DNA to the left and 0.6 kb vaccinia DNA to the right, all in a pUC background.
- the site of deletion within vaccinia sequences is indicated by a triangle in FIG. 6.
- the vaccinia I4L deletion cassette was moved from pSD539 into pRCll, a pUC derivative from which all Beta-galactosidase sequences have been removed and replaced with a polylinker region (Colinas et al., 1990).
- pSD539 was cut with EcoRI/PstI and the 1.2 kb fragment isolated. This fragment was ligated into pRCll cut with EcoRI/PstI (2.35 kb) , forming pSD548.
- DNA from recombinant vaccinia virus vP866 was analyzed by restriction digests followed by electrophoresis on an agarose gel. The restriction patterns were as expected. Polymerase chain reactions (PCR) (Engelke et al., 1988) using vP866 as template and primers flanking the six deletion loci detailed above produced DNA fragments of the expected sizes. Sequence analysis of the PCR generated fragments around the areas of the deletion junctions confirmed that the junctions were as expected. Recombinant vaccinia virus vP866, containing the six engineered deletions as described above, was designated vaccinia vaccine strain "NYVAC.”
- telomere sequence under the control of the vaccinia H6 promoter (Taylor et al., 1988a,b) was inserted into TK deletion plasmid pSD513.
- pSD513 is identical to plasmid pSD460 (FIG. 1) except for the presence of a polylinker region.
- the polylinker region was inserted by cutting pSD460 with Smal and ligating the plasmid vector with annealed synthetic oligonucleotides
- VQ1A/VQ1B (SEQ ID NO:25/SEQ ID NO:26)
- pSD513 was cut with Smal and ligated with a Smal ended 1.8 kb cassette containing the gene encoding the rabies glycoprotein G gene under the control of the vaccinia H6 promoter (Taylor et al., 1988a,b) .
- the resulting plasmid was designated pRW842.
- pRW842 was used as donor plasmid for recombination with NYVAC rescuing virus (vP866) .
- Recombinant vaccinia virus vP879 was identified by plaque hybridization using 32 p- labelled DNA probe to rabies glycoprotein G coding sequences.
- the modified recombinant viruses of the present invention provide advantages as recombinant vaccine vectors.
- the attenuated virulence of the vector advantageously reduces the opportunity for the possibility of a runaway infection due to vaccination in the vaccinated individual and also diminishes transmission from vaccinated to unvaccinated individuals or contamination of the environment.
- the modified recombinant viruses are also advantageously used in a method for expressing a gene product in a cell cultured in vitro by introducing into the cell the modified recombinant virus having foreign DNA which codes for and expresses gene products in the cell.
- This example describes the development of ALVAC, a canarypox virus vector and, of a canarypox-rabies recombinant designated as ALVAC-RG (vCP65) and its safety and efficacy.
- the parental canarypox virus (Rentschler strain) is a vaccinal strain for canaries.
- the vaccine strain was obtained from a wild type isolate and attenuated through more than 200 serial passages on chick embryo fibroblasts.
- a master viral seed was subjected to four successive plaque purifications under agar and one plaque clone was amplified through five additional passages after which the stock virus was used as the parental virus in in vitro recombination tests.
- the plaque purified canarypox isolate is designated ALVAC.
- ACTCTCAAAAGCTTCCCGGGAATTCTAGCTAGCTAGTTTTTATAAA RW146 (SEQ ID NO:30) : GATCTTTATAAAAACTAGCTAGCTAGAATTCCCGGGAAGCTTTTGAGAGT Oligonucleotides RW145 and RW146 were annealed and inserted into the pRW 764.5 Rsal and Bglll vector described above. The resulting plasmid is designated pRW831.
- Oligonucleotides A through E which overlap the translation initiation codon of the H6 promoter with the ATG of rabies G, were cloned into pUC9 as pRW737. Oligonucleotides A through E contain the H6 promoter, starting at Nrul. through the Hindlll site of rabies G followed by Bglll. Sequences of oligonucleotides A through E ((SEQ ID NO:31) -(SEQ ID NO:35)) are: A (SEQ ID NO: 31): CTGAAATTATTTCATTATCGCGATATCCGTTAA
- GTTTGTATCGTAATGGTTCCTCAGGCTCTCCTGTTTGT B (SEQ ID NO:32): CATTACGATACAAACTTAACGGATATCGCGATAA TGAAATAATTTCAG
- TTCCCTATTTACACGATCCCAGACAAGCTTAGATCTCAG D (SEQ ID NO:34): CTGAGATCTAAGCTTGTCTGGGATCGTGTAAATA
- GGGAATTTCCCAAAACA E (SEQ ID NO:35): CAACGGAAAAACCAGAAGGGGTACAAACAGGAGA
- Oligonucleotides A through E were kinased, annealed (95°C for 5 minutes, then cooled to room temperature) , and inserted between the PvuII sites of pUC9.
- the resulting plasmid, pRW737 was cut with Hindlll and Bglll and used as a vector for the 1.6 kbp HindiII-Bglll fragment of ptgl55PR0 (Kieny et al., 1984) generating pRW739.
- the ptgl55PR0 Hindlll site is 86 bp downstream of the rabies G translation initiation codon.
- Bglll is downstream of the rabies G translation stop codon in ptgl55PR0.
- pRW739 was partially cut with Nrul. completely cut with Bglll. and a 1.7 kbp Nrul-Bglll fragment, containing the 3 ' end of the H6 promoter previously described (Taylor et al., 1988a,b; Guo et al., 1989; Perkus et al., 1989) through the entire rabies G gene, was inserted between the Nrul and BamHI sites of pRW824. The resulting plasmid is designated pRW832. Insertion into pRW824 added the H6 promoter 5' of Nrul.
- the pRW824 sequence of BamHI followed by Smal is (SEQ ID NO:36): GGATCCCCGGG.
- pRW824 is a plasmid that contains a nonpertinent gene linked precisely to the vaccinia virus H6 promoter. Digestion with Nrul and BamHI completely excised this nonpertinent gene. The 1.8 kbp pRW832 Smal fragment, containing H6 promoted rabies G, was inserted into the Smal of pRW831, to form plasmid pRW838. Development of ALVAC-RG. Plasmid pRW838 was transfected into ALVAC infected primary CEF cells by using the calcium phosphate precipitation method previously described (Panicali et al., 1982; Piccini et al., 1987).
- ALVAC-RG vCP65
- Figs. 9A and 9B The correct insertion of the rabies G gene into the ALVAC genome without subsequent mutation was confirmed by sequence analysis.
- Immunofluorescence During the final stages of assembly of mature rabies virus particles, the glycoprotein component is transported from the golgi apparatus to the plasma membrane where it accumulates with the carboxy terminus extending into the cytoplasm and the bulk of the protein on the external surface of the cell membrane.
- immunofluorescence was performed on primary CEF cells infected with ALVAC or ALVAC-RG. Immunofluorescence was performed as previously described (Taylor et al., 2990) using a rabies G monoclonal antibody. Strong surface fluorescence was detected on CEF cells infected with ALVAC-RG but not with the parental ALVAC.
- ALVAC and ALVAC-RG were inoculated in 10 sequential blind passages in three cell substrates: (l) Primary chick embryo fibroblast (CEF) cells produced from 11 day old white leghorn embryos;
- Vero cells - a continuous line of African Green monkey kidney cells (ATCC # CCL81) ;
- the initial inoculation was performed at an m.o.i. of 0.1 pfu per cell using three 60mm dishes of each cell substrate containing 2 X 10 6 cells per dish.
- One dish was inoculated in the presence of 40 ⁇ g/ml of Cytosine arabinoside (Ara C) , an inhibitor of DNA replication. After an absorption period of 1 hour at 37°C, the inoculum was removed and the monolayer washed to remove unabsorbed virus.
- Ara C Cytosine arabinoside
- sample t7A 5ml of EMEM + 2% NBCS on two dishes (samples to and t7) and 5ml of EMEM + 2% NBCS containing 40 ⁇ g/ml Ara C on the third (sample t7A) .
- Sample to was frozen at -70°C to provide an indication of the residual input virus.
- Samples t7 and t7A were incubated at 37°C for 7 days, after which time the contents were harvested and the cells disrupted by indirect sonication.
- sample t7 of each cell substrate was inoculated undiluted onto three dishes of the same cell substrate (to provide samples to, t7 and t7A) and onto one dish of primary CEF cells. Samples to, t7 and t7A were treated as for passage one. The additional inoculation on CEF cells was included to provide an amplification step for more sensitive detection of virus which might be present in the non-avian cells.
- Virus yield in each sample was then determined by plaque titration on CEF monolayers under agarose. Summarized results of the experiment are shown in Tables 1 and 2. The results indicate that both the parental ALVAC and the recombinant ALVAC-RG are capable of sustained replication on CEF monolayers with no loss of titer. In Vero cells, levels of virus fell below the level of detection after 2 passages for ALVAC and 1 passage for ALVAC-RG. In MRC-5 cells, a similar result was evident, and no virus was detected after 1 passage. Although the results for only four passages are shown in Tables l and 2 the series was continued for 8 (Vero) and 10 (MRC-5) passages with no detectable adaptation of either virus to growth in the non-avian cells.
- mice Inoculation of Mice.
- Groups of mice were inoculated with 50 to 100 ⁇ l of a range of dilutions of different batches of VCP65. Mice were inoculated in the footpad. On day 14, mice were challenged by intracranial inoculation of from 15 to 43 mouse LD 50 of the virulent CVS strain of rabies virus. Survival of mice was monitored and a protective dose 50% (PD 50 ) calculated at 28 days post-inoculation.
- PD 50 protective dose 50%
- Chicken embryo fibroblast cells produced from 11 day old white leghorn embryos were included as a positive control. All inoculations were performed on preformed monolayers of 2 X 10 6 cells as discussed below.
- Each sample of 2 X 10 6 cells was resuspended in 0.5 ml phosphate buffered saline (PBS) containing 40 mM EDTA and incubated for 5 minutes at 37°C.
- An equal volume of 1.5% agarose prewarmed at 42°C and containing 120 mM EDTA was added to the cell suspension and gently mixed. The suspension was transferred to an agarose plug mold and allowed to harden for at least 15 min.
- the agarose plugs were then removed and incubated for 12-16 hours at 50°C in a volume of lysis buffer (1% sarkosyl, 100 ⁇ g/ml proteinase K, 10 mM Tris HCl pH 7.5, 200 mM EDTA) that completely covers the plug.
- the lysis buffer was then replaced with 5.0 ml sterile 0.5 X TBE (44.5 mM Tris-borate, 44.5 mM boric acid, 0.5 mM EDTA) and equilibrated at 4°C for 6 hours with 3 changes of TBE buffer.
- the viral DNA within the plug was fractionated from cellular RNA and DNA using a pulse field electrophoresis system.
- Electrophoresis was performed for 20 hours at 180 V with a ramp of 50-90 sec at 15°C in 0.5 X TBE.
- the DNA was run with lambda DNA molecular weight standards. After electrophoresis the viral DNA band was visualized by staining with ethidium bromide.
- the DNA was then transferred to a nitrocellulose membrane and probed with a radiolabelled probe prepared from purified ALVAC genomic DNA.
- Dishes were inoculated with recombinant or parental virus at a multiplicity of 10 pfu/cell, allowing an additional dish as an uninfected virus control.
- Infected cells were labelled overnight (approximately 16 hours) , then lysed by the addition of buffer A lysis buffer.
- Immunoprecipitation was performed as previously described (Taylor et al., 1990) using a rabies G specific monoclonal antibody.
- Results Estimation of Viral Yield. The results of titration for yield at 72 hours after inoculation at 0.1 pfu per cell are shown in Table 5. The results indicate that while a productive infection can be attained in the avian cells, no increase in virus yield can be detected by this method in the four non-avian cell systems.
- DNA from the cell lysates was fractionated by electrophoresis, transferred to nitrocellulose and probed for the presence of viral specific DNA.
- ALVAC-RG infected CEF cells at 72 hours post-infection exhibited a strong band in the region of approximately 350 kbp representing ALVAC- specific viral DNA accumulation. No such band is detectable when the culture is incubated in the presence of the DNA synthesis inhibitor, cytosine arabinoside.
- Equivalent samples produced in Vero cells showed a very faint band at approximately 350 kbp in the ALVAC-RG infected Vero cells at time zero. This level represented residual virus. The intensity of the band was amplified at 72 hours post-infection indicating that some level of viral specific DNA replication had occurred in Vero cells which had not resulted in an increase in viral progeny.
- results of this experiment indicated that in the human cell lines analyzed, although the ALVAC-RG recombinant was able to initiate an infection and express a foreign gene product under the transcriptional control of the H6 early/late vaccinia virus promoter, the replication did not proceed through DNA replication, nor was there any detectable viral progeny produced. In the Vero cells, although some level of ALVAC-RG specific DNA accumulation was observed, no viral progeny was detected by these methods. These results would indicate that in the human cell lines analyzed the block to viral replication occurs prior to the onset of DNA replication, while in Vero cells, the block occurs following the onset of viral DNA replication.
- mice were challenged 14 days later by the intracranial route with 300 ⁇ l of the CVS strain of rabies virus containing from 15 to 43 mouse LD 50 as determined by lethality titration in a control group of mice. Potency, expressed as the PD 50 (Protective dose 50%) , was calculated at 14 days post-challenge. The results of the experiment are shown in Table 6. The results indicated that ALVAC-RG was consistently able to protect mice against rabies virus challenge with a PD 50 value ranging from 3.33 to 4.56 with a mean value of 3.73 (STD 0.48).
- mice were inoculated intracranially with 50 ⁇ l of virus containing 6.0 log 10 TCID 50 of ALVAC-RG or with an equivalent volume of an uninfected cell suspension. Mice were sacrificed on days l, 3 and 6 post-inoculation and their brains removed, fixed and sectioned. Histopathological examination showed no evidence for neurovirulence of ALVAC-RG in mice.
- Pass 2 represents the amplification in CEF cells of the 7 day sample from Pass 1.
- b Titer expressed as log, 0 pfu per ml
- c Not Detectable
- vCP82 is a canarypox virus recombinant expressing the measles virus fusion and hemagglutinin genes. Table 5. Analysis of yield in avian and non-avian cells inoculated with ALVAC-RG
- 25 a See Table 9 for schedule of inoculations.
- b.Animals 176L and 185L received 8.0 log 10 pfu by the oral route in 5 ml Tang.
- Animal 187L received 7.0 log 10 pfu by oral route not in Tang.
- d Titers expressed as reciprocal of last dilution showing inhibition of fluorescence in an RFFI test.
- ALVAC-RG (vCP65) was generated as described in Example 9 and FIGS. 9A and 9B.
- ALVAC-RG VCP65 was grown in primary CEF derived from specified pathogen free eggs. Cells were infected at a multiplicity of 0.1 and incubated at 37°C for three days.
- the vaccine virus suspension was obtained by ultrasonic disruption in serum free medium of the infected cells; cell debris were then removed by centrifugation and filtration.
- the resulting clarified suspension was supplemented with lyophilization stabilizer (mixture of amino-acids) , dispensed in single dose vials and freeze dried.
- Three batches of decreasing titer were prepared by ten-fold serial dilutions of the virus suspension in a mixture of serum free medium and lyophilization stabilizer, prior to lyophilization. Quality control tests were applied to the cell substrates, media and virus seeds and final product with emphasis on the search for adventitious agents and inocuity in laboratory rodents. No undesirable trait was found.
- VERO or MRC-5 cells do not support the growth of ALVAC-RG (vCP65) ; a series of eight (VERO) and 10 (MRC) blind serial passages caused no detectable adaptation of the virus to grow in these non avian lines.
- Analyses of human cell lines MRC-5, WISH, Detroit 532, HEL, HNK or EBV-transformed lymphoblastoid cells infected or inoculated with ALVAC-RG (vCP65) showed no accumulation of virus specific DNA suggesting that in these cells the block in replication occurs prior to DNA synthesis.
- ALVAC-RG vCP65
- canaries chickens, ducks, geese, laboratory rodents (suckling and adult mice) , hamsters, guinea-pigs, rabbits, cats and dogs, squirrel monkeys, rhesus macaques and chimpanzees, were inoculated with doses ranging from 10 5 to 10 8 pfu.
- routes were used, most commonly subcutaneous, intramuscular and intradermal but also oral (monkeys and mice) and intracerebral (mice) .
- ALVAC-RG (vCP65) caused a ⁇ • take" lesion at the site of scarification with no indication of disease or death.
- Intradermal inoculation of rabbits resulted in a typical poxvirus inoculation reaction which did not spread and healed in seven to ten days. There was no adverse side effects due to canarypox in any of the animal tests.
- Immunogenicity was documented by the development of anti-rabies antibodies following inoculation of ALVAC-RG (VCP65) in rodents, dogs, cats, and primates, as measured by Rapid Fluorescent Focus Inhibition Test (RFFIT) . Protection was also demonstrated by rabies virus challenge experiments in mice, dogs, and cats immunized with ALVAC-RG (vCP65) .
- the trial was designated as a dose escalation study.
- Three batches of experimental ALVAC-RG (vCP65) vaccine were used sequentially in three groups of volunteers
- ALVAC-RG Group C
- HDC vaccine Six months later, the recipients of the highest dosage of ALVAC-RG (vCP65) (Group C) and HDC vaccine were offered a third dose of vaccine; they were then randomized to receive either the same vaccine as previously or the alternate vaccine. As a result, four groups were formed corresponding to the following immunization scheme: l. HDC, HDC - HDC; 2. HDC, HDC - ALVAC-RG (VCP65) ; 3. ALVAC-RG (VCP65) , ALVAC-RG (VCP65) - HDC; 4. ALVAC-RG (VCP65) , ALVAC-RG (vCP65) , ALVAC-RG (VCP65) .
- the levels of neutralizing antibodies to rabies were determined using the Rapid Fluorescent Focus Inhibition test (RFFIT) (Smith et al., 1973).
- Canarypox antibodies were measured by direct ELISA.
- the antigen a suspension of purified canarypox virus disrupted with 0.1% Triton X100, was coated in microplates. Fixed dilutions of the sera were reacted for two hours at room temperature and reacting antibodies were revealed with a peroxidase labelled anti-human IgG goat serum. The results are expressed as the optical density read at 490nm.
- protective titers were achieved in 0/3 of Group A, 2/3 of Group B and 9/9 of Group C recipients of ALVAC-RG (vCP65) vaccine and persisted in all 10 HDC recipients.
- the rabies antibody titers had substantially decreased in all subjects but remained above the minimum protective titer of 0.5 IU/ml in 5/10 HCD recipients and in 5/9 ALVAC-RG (vCP65) recipients; the geometric mean titers were 0.51 and 0.45 IU/ml in groups HCD and C, respectively.
- Antibodies to the Canarypox virus (Table 13) .
- Booster Injection The vaccine was similarly well tolerated six months later, at the time of the booster injection: fever was noted in 2/9 HDC booster recipients and in 1/10 ALVAC-RG (vCP65) booster recipients.
- Figs. 11A-11D show graphs of rabies neutralizing antibody titers (Rapid Fluorescent Focus Inhibition Test or RFFIT, IU/ml) : Booster effect of HDC and vCP65 (10 5,5 TCID 50 ) in volunteers previously immunized with either the same or the alternate vaccine. Vaccines were given at days 0, 28 and 180. Antibody titers were measured at days 0, 7, 28, 35, 56, 173, and 187 and 208. As shown in FIGS.
- the booster dose given resulted in a further increase in rabies antibody titers in every subject whatever the immunization scheme.
- the ALVAC-RG (vCP65) booster globally elicited lower immune responses than the HDC booster and the ALVAC-RG (VCP65) , ALVAC-RG (VCP65) - ALVAC-RG (VCP65) group had significantly lower titers than the three other groups.
- the ALVAC-RG (vCP65) booster injection resulted in an increase in canarypox antibody titers in 3/5 subjects who had previously received the HDC vaccine and in all five subjects previously immunized With ALVAC-RG (VCP65) .
- Rabies neutralizing antibodies were assayed with the Rapid Fluorescent Focus Inhibition Test (RFFIT) which is known to correlate well with the sero neutralization test in mice. Of 9 recipients of 10 5 * 5 TCID 50 , five had low level responses after the first dose. Protective titers of rabies antibodies were obtained after the second injection in all recipients of the highest dose tested and even in 2 of the 3 recipients of the medium dose. In this study, both vaccines were given subcutaneously as usually recommended for live vaccines, but not for the inactivated HDC vaccine.
- RFFIT Rapid Fluorescent Focus Inhibition Test
- this Example clearly demonstrates that a non- replicating poxvirus can serve as an immunizing vector in humans, with all of the advantages that replicating agents confer on the immune response, but without the safety problem created by a fully permissive virus.
- suitable dosages and modes or routes for administration or immunization of recombinants containing either rabies or other coding, or expression products thereof, are within the ambit of the skilled artisan as well modes for in vitro expression.
- mice Male outbred Swiss Webster mice were purchased from Taconic Farms (Germantown, NY) and maintained on mouse chow and water ad libitum until use at 3 weeks of age ("normal" mice) . Newborn outbred Swiss Webster mice were of both sexes and were obtained following timed pregnancies performed by Taconic Farms. All newborn mice used were delivered within a two day period.
- ALVAC was derived by plaque purification of a canarypox virus population and was prepared in primary chick embryo fibroblast cells (CEF) . Following purification by centrifugation over sucrose density gradients, ALVAC was enumerated for plaque forming units in CEF cells.
- the WR(L) variant of vaccinia virus was derived by selection of large plaque phenotypes of WR (Panicali et al., 1981).
- the Wyeth New York State Board of Health vaccine strain of vaccinia virus was obtained from Pharmaceuticals Calf Lymph Type vaccine Dryvax, control number 302001B.
- Copenhagen strain vaccinia virus VC-2 was obtained from Institut Merieux, France.
- Vaccinia virus strain NYVAC was derived from Copenhagen VC-2. All vaccinia virus strains except the Wyeth strain were cultivated in Vero African green monkey kidney cells, purified by sucrose gradient density centrifugation and enumerated for plaque forming units on Vero cells. The Wyeth strain was grown in CEF cells and enumerated for plaque forming units in CEF cells. Inoculations. Groups of 10 normal mice were inoculated intracranially (ic) with 0.05 ml of one of several dilutions of virus prepared by 10-fold serially diluting the stock preparations in sterile phosphate- buffered saline. In some instances, undiluted stock virus preparation was used for inoculation. Groups of 10 newborn mice, 1 to 2 days old, were inoculated ic similarly to the normal mice except that an injection volume of 0.03 ml was used.
- mice All mice were observed daily for mortality for a period of 14 days (newborn mice) or 21 days (normal mice) after inoculation. Mice found dead the morning following inoculation were excluded due to potential death by trauma.
- the lethal dose required to produce mortality for 50% of the experimental population was determined by the proportional method of Reed and Muench.
- Preformed monolayers of avian or non-avian cells were inoculated with 10 pfu per cell of parental NYVAC (vP866) or NYVAC-RG (vP879) virus.
- the inoculation was performed in EMEM free of methionine and supplemented with 2% dialyzed fetal bovine serum. After a one hour incubation, the inoculum was removed and the medium replaced with EMEM (methionine free) containing 20 ⁇ Ci/ml of 35 S-methionine.
- the rabbit was euthanized and skin biopsy specimens taken from each of the inoculation sites were aseptically prepared by mechanical disruption and indirect sonication for virus recovery. Infectious virus was assayed by plaque titration on CEF monolayers.
- mice Virulence in Mice. Groups of ten mice, or five in the nude mice experiment, were inoculated ip with one of several dilutions of virus in 0.5 ml of sterile PBS. Reference is also made to Example 11.
- LD 50 The lethal dose required to produce 50% mortality (LD 50 ) was determined by the proportional method of Reed and Muench (Reed and Muench 1938).
- FIG. 10 schematically depicts the ORFs deleted to generate NYVAC. At the top of FIG. 10 is depicted the Hindlll restriction map of the vaccinia virus genome (VC-2 plaque isolate, COPENHAGEN strain) .
- MRC-5 and DETROIT 532 Consistent with the low levels of virus yields obtained in the human-derived cell lines, MRC-5 and DETROIT 532, detectable but reduced levels of NYVAC- specific DNA accumulation were noted.
- NYVAC-specific viral DNA accumulation was not observed in any of the other human-derived cells.
- a rabbit was inoculated intradermally at multiple sites with 0.1 ml PBS containing 10 6 , 10 7 or 10 8 pfu of VC-2, WR, WYETH or NYVAC.
- 10 7 pfu dose was located above the backspine, flanked by the 10 6 and 10 8 doses.
- Sites of inoculation were observed daily for 11 days.
- WR elicited the most intense response, followed by VC-2 and WYETH (Table 18) . Ulceration was first observed at day 9 for WR and WYETH and day 10 for VC-2.
- Sites inoculated with NYVAC or control PBS displayed no induration or ulceration.
- skin samples from the sites of inoculation were excised, mechanically disrupted, and virus was titrated on CEF cells. The results are shown in Table 18. In no case was more virus recovered at this timepoint than was administered.
- Recovery of vaccinia strain, WR was approximately 10 6 pfu of virus at each site irrespective of amount of virus administered.
- Recovery of vaccinia strains WYETH and VC- 2 was 10 3 to 10 4 pfu regardless of amount administered. No infectious virus was recovered from sites inoculated with NYVAC.
- mice inoculated with WR (10 3 to 10 4 pfu) , WYETH (5 x 10 7 or 5 x 10 8 pfu) or VC-2 (10 4 to 10 9 pfu) displayed disseminated lesions typical of poxviruses first on the toes, then on the tail, followed by severe orchitis in some animals.
- mice infected with WR or WYETH In mice infected with WR or WYETH, the appearance of disseminated lesions generally led to eventual death, whereas most mice infected with VC-2 eventually recovered.
- Calculated LD 50 values are given in Table 19.
- mice inoculated with VC-2 began to display lesions on their toes (red papules) and 1 to 2 days later on the tail. These lesions occurred between 11 and 13 days post-inoculation (pi) in mice given the highest doses (10 9 , 10 8 , 10 7 and 10 6 pfu) , on day 16 pi in mice given 10 5 pfu and on day 21 pi in mice given 10 4 pfu.
- mice inoculated with 10 3 and 10 2 pfu during the 100 day observation period No lesions were observed in mice inoculated with 10 3 and 10 2 pfu during the 100 day observation period. Orchitis was noticed on day 23 pi in mice given 10 9 and 10 8 pfu, and approximately 7 days later in the other groups (10 7 to 10 4 pfu) . Orchitis was especially intense in the 10 9 and 10 8 pfu groups and, although receding, was observed until the end of the 100 day observation period. Some pox-like lesions were noticed on the skin of a few mice, occurring around 30-35 days pi. Most pox lesions healed normally between 60-90 days pi.
- mice inoculated with 10 4 pfu of the WR strain of vaccinia started to display pox lesions on Day 17 pi. These lesions appeared identical to the lesions displayed by the VC-2 injected mice (swollen toes, tail) . Mice inoculated with 10 3 pfu of the WR strain did not develop lesions until 34 days pi. Orchitis was noticed only in the mice inoculated with the highest dose of WR (10 4 pfu) . During the latter stages of the observation period, lesions appeared around the mouth and the mice stopped eating. All mice inoculated with 10 4 pfu of WR died or were euthanized when deemed necessary between 21 days and 31 days pi.
- mice injected with 10 3 pfu of WR died or were euthanized when deemed necessary between 35 days and 57 days pi. No deaths were observed in mice inoculated with lower doses of WR (1 to 100 pfu) .
- CY-treated mice provided a more sensitive model for assaying poxvirus virulence than did nude mice.
- LD 50 values for the WR, WYETH, and VC-2 vaccinia virus strains were significantly lower in this model system than in the nude mouse model.
- CY-treated mice injected with NYVAC or ALVAC did not develop lesions. However, unlike nude mice, some deaths were observed in CY-treated mice challenged with NYVAC or ALVAC, regardless of the dose. These random incidences are suspect as to the cause of death.
- mice injected with all doses of WYETH displayed pox lesions on their tail and/or on their toes between 7 and 15 days pi. In addition, the tails and toes were swollen. Evolution of lesions on the tail was typical of pox lesions with formation of a papule, ulceration and finally formation of a scab.
- Mice inoculated with all doses of VC-2 (1.65 x 10 5 to 1.65 x 10 9 ) also developed pox lesions on their tails and/or their toes analogous to those of WYETH injected mice. These lesions were observed between 7-12 days post inoculation. No lesions were observed on mice injected with lower doses of WR virus, although deaths occurred in these groups.
- Table 20 demonstrates that the PD 50 values obtained with the highly attenuated NYVAC vector are identical to those obtained using a COPENHAGEN-based recombinant containing the rabies glycoprotein gene in the tk locus (Kieny et al., 1984) and similar to PD 50 values obtained with ALVAC-RG, a canarypox based vector restricted to replication to avian species. Observations. NYVAC, deleted of known virulence genes and having restricted in vitro growth characteristics, was analyzed in animal model systems to assess its attenuation characteristics.
- Results from analyses in immunocompromised mouse models (nude and CY-treated) also demonstrate the relatively high attenuation characteristics of NYVAC, as compared to WR, WYETH and COPENHAGEN strains (Tables 17 and 18) .
- the deletion of multiple virulence-associated genes in NYVAC shows a synergistic effect with respect to pathogenicity.
- Another measure of the inocuity of NYVAC was provided by the intradermal administration on rabbit skin (Tables 17 and 18) .
- Example 10 demonstrate the highly attenuated nature of NYVAC relative to WR, and the previously utilized vaccinia virus vaccine strains, WYETH and COPENHAGEN.
- the pathogenic profile of NYVAC, in the animal model systems tested was similar to that of ALVAC, a poxvirus known to productively replicate only in avian species.
- NYVAC-based vaccine candidates have been shown to be efficacious.
- NYVAC recombinants expressing foreign gene products from a number of pathogens have elicited immunological responses towards the foreign gene products in several animal species, including primates.
- a NYVAC-based recombinant expressing the rabies glycoprotein was able to protect mice against a lethal rabies challenge.
- the potency of the NYVAC-based rabies glycoprotein recombinant was comparable to the PD 50 value for a COPENHAGEN-based recombinant containing the rabies glycoprotein in the tk locus (Table 20) .
- NYVAC-based recombinants have also been shown to elicit measles virus neutralizing antibodies in rabbits and protection against pseudorabies virus and Japanese encephalitis virus challenge in swine.
- the highly attenuated NYVAC strain confers safety advantages with human, animal, medical and veterinary applications (Tartaglia et al., 1992).
- the use of NYVAC as a general laboratory expression vector system may greatly reduce the biological hazards associated with using vaccinia virus.
- Example 10 show NYVAC to be highly attenuated: a) no detectable induration or ulceration at site of inoculation (rabbit skin) ; b) rapid clearance of infectious virus from intradermal site of inoculation (rabbit skin) ; c) absence of testicular inflammation (nude mice) ; d) greatly reduced virulence (intracranial challenge, both three- week old and newborn mice) ; e) greatly reduced pathogenicity and failure to disseminate in immunodeficient subjects (nude and cyclophosphamide treated mice) ; and f) dramatically reduced ability to replicate on a variety of human tissue culture cells. Yet, in spite of being highly attenuated, NYVAC, as a vector, retains the ability to induce strong immune responses to extrinsic antigens.
- a Yield of NYVAC at 72 hours post-infection expressed as a percentage of yield of VAC-2 after 72 hours on the same cell line.
- b Titer expressed as LOG ⁇ pfu per ml.
- c Sample was incubated in the presence of 40 ⁇ g/ml of cytosine arabinoside. d Not determined.
- a Calculated 50% lethal dose (pfu) for nude or cyclophosphamide treated mice by the indicated vaccinia viruses and for ALVAC by intraperitoneal route.
- b 5 out of 10 mice died at the highest dose of 5 x 10 8 pfu.
- mice Four to six week old mice were inoculated in the footpad with 50-1 OO ⁇ l of a range of dilutions (2.0 - 8.0 log 10 tissue culture infection dose 50% (TCID ⁇ ) of either the W-RG (Kieny et al., 1984), ALVAC-RG (vCP65) or NYVAC-RG (vP879).
- mice of each group were challenged by intracranial inoculation of 30 ⁇ l of a live CVS strain rabies virus corresponding to 15 lethal dose 50% (LD ⁇ ) per mouse.
- LD ⁇ lethal dose 50%
- mice were counted and a protective dose 50% (PD ⁇ was calculated.
- NYVAC and ALVAC HTLV-I envelope recombinant vaccines were constructed using plasmid DNA from the HTLV-I 1711 molecular clone obtained from a culture of primary cells of a West African patient (Cardoso, 1989) .
- Phylogenetically HTLV-I 1711 belongs to the cosmopolitan family of HTLV-I (Gudin, 1992) .
- a donor plasmid containing the I3L-promoted human T- cell lymphotropic virus type I (HTLV-I) envelope gene was generated by the following procedure.
- PCR-HTLV 18 containing the I3L promoter fused to the 5'-end of the HTLV-I envelope gene, was generated from the plasmid, p M102, with the oligonucleotide primers, MW093 (SEQ ID NO:37; 5'-
- ATCATCGGTACCACATCATGCAGTGGTTAAAC-3' ATCATCGGTACCACATCATGCAGTGGTTAAAC-3'
- MW110 SEQ ID NO:38; 5'-GGCGAGAAACTTACCCATGATTAAACCTAAATAATTG-3'
- a 1,500 bp PCR fragment, pCR-HTLV21, containing the 3'-end of the I3L promoter fused to the entire HTLV-I envelope gene was generated from the plasmid, pl7-SST (containing entire HTLV-I nucleotide sequence) , with the oligonucleotide primers, MW113 (SEQ ID NO:39; 5'- CAATTATTTAGGTTTAATCATGGGTAAGTTTCTCGCC-3') and MW116 (SEQ ID NO:40; 5'-ATCATCTCTAGAATAAAAATTACAGGGATGACTCAGGG-3') .
- the I3L-promoted envelope gene was then cloned into pBSK. This was accomplished in 3 steps. 1) The 13L promoter and the 5'-end of the envelope gene was cloned into pBSK.
- the I3L promoter and the 5'-end of the envelope gene was then cloned upstream from the 3'-end of the envelope gene. This was accomplished by cloning the 1,100 bp Kpnl fragment of pMAW015, containing the I3L promoter and the 5'-end of the envelope gene, into the Kpnl site of pMAW013.
- the plasmid generated by this manipulation is called pMAW016.
- the I3L-promoted envelope gene was then cloned between canarypox C5 flanking arms. This was accomplished by cloning the 1,600 bp partial Kpnl-Xbal fragment of pMAW16, containing the I3L-promoted envelope gene, into the 4,800 bp KpnI-Xbal fragment of pVQC5LSP6. The plasmid generated by this manipulation is called pMAW017.
- pC5LSP was digested with BamHI and ligated to annealed oligonucleotides CP32 (SEQ ID NO:41) (5'- GATCTTAATTAATTAGTCATCAGGCAGGGCGAGAACGA
- pVQC5LSP6 GACTATCTGCTCGTTAATTAATTAGGTCGACG-3'
- CP33 SEQ ID NO:42
- oligonucleotides CP26 (SEQ ID NO:43) (5'- GTACGTGACTAATTAGCTATAAAAAGGATCCGGTACCCTCGAGTCTAGAATC GATCCCGGGTTTTTATGACTAGTTAATCAC -3') and CP27 (SEQ ID NO:44)
- vCP65 AVAC-based rabies G recombinant with rabies in C5 locus
- This library was probed with the 0.9 kb PvuII canarypoxvirus genomic fragment contained within pRW764.5 (C5 locus) .
- canarypox DNA sequences contain the original insertion locus.
- a clone containing a 29 kb insert was grown up and designated pHCOSl. From this cosmid containing C5 sequences, a 3.3 kb Cla fragment was subcloned. Sequence analysis from this Clal fragment was used to extend the map of the C5 locus from 1-1372.
- the C5 insertion vector, pC5L was constructed in two steps.
- the 1535 bp left arm was generated by PCR amplification using oligonucleotides C5A (SEQ ID NO:45) (5'-ATCATCGAATTCTGAATGTTAAATGTTATACTTTG) and C5B (SEQ ID NO:46) (GGGGGTACCTTTGAGAGTACCACTTCAG-3') .
- the template DNA was vCP65 genomic DNA. This fragment was cloned into EcoRI/Smal digested pUC8. The sequence was confirmed by standard sequencing protocols.
- the 404 bp right arm was generated by PCR amplification using oligonucleotides C5C (SEQ ID NO:47) (5'-ATCATCCTGCAGGTATTCTAAACTAGGAATAGATG- 3') and C5DA (SEQ ID NO:48) (5'-ATCATCCTGCAGGTATTC TAAACTAGGAATAGATG-3') .
- This fragment was then cloned into the vector previously generated containing the left arm digested with Smal/Pstl. The entire construct was confirmed by standard sequence analysis and designated pC5L. This insertion plasmid enables the insertion of foreign genes into the C5 locus.
- the I3L-promoted envelope gene was then cloned between vaccinia HA flanking arms. This was accomplished by cloning the 1,600 bp partial KpnI-Xbal fragment of pMAW017, containing the I3L-promoted envelope gene, into the 3,600 bp Kpnl-Xbal fragment of pSPHAH6.
- the plasmid generated by this manipulation is called pMAWOl ⁇ .
- Plasmid pSPHAH6 was derived as follows. Plasmid pMP2VCL (containing a polylinker region within vaccinia sequences upstream of the K1L host range gene) was digested within the polylinker with Hindlll and Xhol and ligated to annealed oligonucleotides SPHPRHA A through D (SPHPRHA h (SEQ ID NO:49) 5'-AGCTTCTTTATTC TATACTTAAAAAGTGAAAATAAATACAAAGGTTCTTGAGGGT-3' SPHPRHA B (SEQ ID NO:50) 5'-
- AAATTATTTCATTATCGCGATATCCGTTAAGTTTGTATCGTAC-3' SPHPRHA C (SEQ ID NO:51) 3'-TTATTAGTATTTAATAAAGTAATAGCG CTATAGGCAATTCAAACATAGCATGAGCT-5' SPHPRHA D (SEQ ID NO:52) 3'-AGAAATAAGATATGAATTTTTCACTTT TATTTATGTTTCCAAGAACTCCCAACACAATTTAACTTTCGCTCT-5') generating pSP126 containing a Hindlll site, H6 promoter -124 through -1 (Perkus et al., 1989) and Xhol. Kpnl. Smal. SacI and EcoRI sites.
- Plasmid pSD544 (containing vaccinia sequences surrounding the site of the HA gene replaced with a polylinker region and translation termination codons in six reading frames) was digested with Xhol within the polylinker, filled in with the Klenow fragment of DNA polymerase I and treated with alkaline phosphatase.
- RECOMBINANT EXPRESSING HTLV-I ENV pMAW017 obtained as described in Example 12, was used in in vitro recombination experiments with ALVAC as the rescuing virus to yield VCP203.
- the HTLV-I cell-associated challenge was prepared using a short-term coculture of human cord blood cells infected with HTLV-I B0U , a West Indican isolate which also belongs to the cosmopolitan HTLV type (Gassain, 1992) .
- Four rabbit pairs were inoculated with 8xl0 4 , 4xl0 4 , 2xl0 4 and lxlO 4 HTLV-I B0U -infected human cells by the intravenous (I.V.) route as indicated in Table 22.
- virus isolation was performed several times from purified peripheral blood mononuclear cells (PBMC) either by direct culture or by cocultivation with human cord blood cells.
- PBMC peripheral blood mononuclear cells
- each pair of rabbits inoculated with 8 or 4xl0 4 cells become infected after viral exposure. Only one of two animals were infected using 2xl0 4 cells whereas none of the rabbits were infected using lxlO 4 as judged by virus isolation and polymerase chain reaction (PCR) . Thus, a dose of 5xl0 4 cells was chosen to challenge the vaccinated animals. Since only 30% of the HTLV-I B0U -infected human cells used in the in vitro titration study were stained by a monoclonal antibody against the HTLV-I pl9 gag antigen in an immunofluorescence assay, the challenge does correspond to approximately 1.5xl0 4 cells expressing virus.
- Animal 34438 was PCR positive on one occasion, but virus was never isolated from its PBMC nor from its spleen (collected post-mortem) .
- Fig. 12 Detection of antibodies against HTLV-I in the sera of animals in the ALVAC env prime boost protocol is shown in Fig. 12.
- the upper portion of Fig. 12 represents the vaccination protocol for each animal group.
- the numbers represent the time (months) of each inoculation.
- the Western blot was performed using strips from Cellular Products (Buffalo, NY) and the sera from the immunized animals are as follows: A, 1 week after the first ALVAC boost; B, after the second protein boost; C, at time of challenge; and D, 4 months after live virus challenge.
- Fig. 13 Serological response in the NYVAC env vaccinated and challenged animals is shown in Fig. 13.
- the outline of the vaccination protocol is displayed at the top of Fig. 13.
- the numbers represent the time (months) of each inoculation.
- the sera tested in Western blot were obtained at the following times: A, before immunization; B, 1 weeks after the first boost; and C, 4 months after challenge.
- Rabbit blood was used as challenged rather than human cells infected with HTLV-I BOU to avoid a readout of the experimental results due to an immune response directed against human cells.
- Four naive animals were used as controls.
- Viral isolation and PCR analysis revealed that all the vaccinated animals, as well as the control animals, became infected by this HTLV-I challenge exposure (Tables 21 and 23) .
- Neutralizing antibodies were measured in all the ALVAC and NYVAC recombinants vaccinated animals, as well as in the controls using a syncytium inhibition assay with C91/PL and 8166 cells as previously described (Benson, 1994) .
- a consistent pattern was observed inasmuch as neutralizing antibodies were not detectable in all animals before viral challenge and only the animals that became infected (as judged by virus isolation and PCR) developed detectable HTLV-I specific neutralizing antibodies.
- the efficacy of the NYVAC and ALVAC HTLV recombinants is not affected by the more highly attenuated and safer nature of the NYVAC and ALVAC poxvirus vectors employed in the HTLV recombinants.
- coli-derived ⁇ -gal fusion proteins generated only minimal anti-HTLV-I and neutralizing antibody titers. This suggests, without wishing to necessarily be bound by any one particular theory, that strong antibody responses might not be necessary for protection from live HTLV-I-infected cell challenge.
- results presented here demonstrate the ability of the NYVAC and ALVAC-HTLV recombinants and products therefrom to be employed in the compositions and utilities aforementioned, for instance, immunological, antigenic or vaccine compositions, or for use in preparing antigens or antibodies for assays, kits or tests, and, for example, as suitable for uses in vaccine or immunization strategies capable of preventing infection by a cell associated retrovirus such as HTLV-I.
- a-10 2 pfu of virus were Inoculated by the I.M. route. b-l. V. Inoculation of 5 x 10* cells Infected with HTLV-l BOl) .
- ADDRESSEE Curtis, Morris & Safford, P.C.
- MOLECULE TYPE cDNA
- MOLECULE TYPE cDNA
- MOLECULE TYPE cDNA
- AAAAATTTAA CAATGGTTAA ACTTCTATTG AACAAAGGTG CTGATACTGA CTTGCTGGAT 1260
- MOLECULE TYPE cDNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07075029A EP1840209A3 (de) | 1995-01-13 | 1996-01-16 | Adeno-assoziierten Virusvektoren und deren Verwendung. |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37266495A | 1995-01-13 | 1995-01-13 | |
US372664 | 1995-01-13 | ||
PCT/US1996/000547 WO1996021727A1 (en) | 1995-01-13 | 1996-01-16 | Immunogenic compositions containing recombinant attenuated poxviruses expressing htlv antigens |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07075029A Division EP1840209A3 (de) | 1995-01-13 | 1996-01-16 | Adeno-assoziierten Virusvektoren und deren Verwendung. |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0805854A1 true EP0805854A1 (de) | 1997-11-12 |
EP0805854A4 EP0805854A4 (de) | 2000-06-07 |
Family
ID=23469144
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96902688A Withdrawn EP0805854A4 (de) | 1995-01-13 | 1996-01-16 | Immunogene zusammensetzungen welche rekombinant abgeschwächte pockenviren enthalten, die ein htlv antigen expremieren |
EP07075029A Withdrawn EP1840209A3 (de) | 1995-01-13 | 1996-01-16 | Adeno-assoziierten Virusvektoren und deren Verwendung. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07075029A Withdrawn EP1840209A3 (de) | 1995-01-13 | 1996-01-16 | Adeno-assoziierten Virusvektoren und deren Verwendung. |
Country Status (4)
Country | Link |
---|---|
EP (2) | EP0805854A4 (de) |
JP (2) | JPH10512151A (de) |
CA (1) | CA2210294C (de) |
WO (1) | WO1996021727A1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7374768B1 (en) | 1990-09-25 | 2008-05-20 | Xenova Research Limited | Viral vaccines |
ATE181108T1 (de) | 1991-08-26 | 1999-06-15 | Immuno Ag | Direkt molekuläre klonierung eines modifizierten genoms eines chordopocken-virus |
DK0758397T3 (da) * | 1994-04-29 | 2005-10-10 | Baxter Healthcare Sa | Rekombinante poxvira med fremmede polynucleotider i essentielle regioner |
US5990091A (en) * | 1997-03-12 | 1999-11-23 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
EP2610265B1 (de) | 2003-05-02 | 2016-11-16 | Centre National de la Recherche Scientifique (C.N.R.S.) | Glut-1 als Rezeptor für HTLV-Hüllen und dessen Verwendungen |
US9777044B2 (en) | 2003-05-02 | 2017-10-03 | Centre National De La Recherche Scientifique (Cnrs) | GLUT-1 as a receptor for HTLV envelopes and its uses |
BRPI1007376B1 (pt) | 2009-01-09 | 2022-03-22 | Centre National De La Recherche Scientifique | Novos ligantes de ligação a receptores e seu uso na detecção de células de interesse biológico |
MX2021007860A (es) * | 2018-12-28 | 2021-10-26 | Transgene | Poxvirux deficiente en m2. |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5833975A (en) * | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
-
1996
- 1996-01-16 EP EP96902688A patent/EP0805854A4/de not_active Withdrawn
- 1996-01-16 EP EP07075029A patent/EP1840209A3/de not_active Withdrawn
- 1996-01-16 WO PCT/US1996/000547 patent/WO1996021727A1/en not_active Application Discontinuation
- 1996-01-16 CA CA002210294A patent/CA2210294C/en not_active Expired - Fee Related
- 1996-01-16 JP JP8521863A patent/JPH10512151A/ja active Pending
-
2007
- 2007-06-22 JP JP2007165148A patent/JP2007254489A/ja not_active Abandoned
Non-Patent Citations (2)
Title |
---|
No further relevant documents disclosed * |
See also references of WO9621727A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP0805854A4 (de) | 2000-06-07 |
CA2210294A1 (en) | 1996-07-18 |
EP1840209A3 (de) | 2008-03-05 |
JP2007254489A (ja) | 2007-10-04 |
WO1996021727A1 (en) | 1996-07-18 |
EP1840209A2 (de) | 2007-10-03 |
CA2210294C (en) | 2003-11-11 |
JPH10512151A (ja) | 1998-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0835133B1 (de) | Rekombinierte pockenvirus-tollwut zusammensetzung und kombinierte zusammensetzungen und deren verwendung | |
US6309647B1 (en) | Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants | |
US6596279B1 (en) | Immunodeficiency recombinant poxvirus | |
US5756102A (en) | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants | |
EP0837928B1 (de) | Rekombinante poxvirus-cytomegalovirus zusammensetzungen und ihre verwendung | |
US5766599A (en) | Trova fowl pox virus recombinants comprising heterologous inserts | |
US5989561A (en) | Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses | |
CA2210294C (en) | Immunogenic compositions containing recombinant attenuated poxviruses expressing htlv antigens | |
WO1996039177A9 (en) | Recombinant poxvirus-calicivirus [rabbit hemorrhagic disease virus (rhdv)] compositions and uses | |
AU717809B2 (en) | Immunogenic compositions containing recombinant attenuated poxviruses expressing HTLV antigens | |
CA2187207C (en) | Poxvirus-canine distemper virus (cdv) recombinants and compositions and methods employing the recombinants | |
CA2153336C (en) | Recombinant virus immunotherapy | |
AU2002300582B2 (en) | Immunodeficiency Recombinant Poxvirus | |
AU702634B2 (en) | Immunodeficiency recombinant poxvirus | |
AU747139B2 (en) | Immunodeficiency recombinant poxvirus | |
AU720448B2 (en) | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants | |
AU2006201066A1 (en) | Immunodeficiency recombinant poxvirus | |
AU6247000A (en) | Recombinant poxvirus-calicivirus (rabbit hemorrhagic disease virus (RHDV)) compositions and uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19970711 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20000420 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20020214 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20070129 |